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ABSTRACT 
Cutaneous melanoma is a malignant tumour that arises from pigmented skin cells – 
melanocytes, represents the most rapidly increasing cancer worldwide which is causing 
significant public health problem. During the past decade a significant progress has 
been made in the understanding of genesis and progression of melanocytic lesions. 
However treatment of malignant melanomas is in a majority of cases limited to surgical 
excision of the primary tumours or metastases. In advanced metastatic disease there are 
few treatment options. The present thesis reviews current knowledge on epidemiology, 
ethiology, pathology and treatment options of the benign and malignant melanocytic 
tumours and concentrates on the analysis of several molecules that are thought to play a 
role in the processes of cell growth, apoptosis, division, motility and adhesion as well 
as regulation of cytoskeletal components, protein phosphorylation, cell-cycle and cell 
survival. Archival material from fine needle aspirates as well as formalin-fixed tumour 
tissue was used in the study. Primary benign and malignant melanocytic tumours as 
well as metastatic melanomas were included in the study. The expression of the 
following proteins in malignant and benign melanocytic tumours was analyzed: S100, 
CD40, CD44, Bcl-2, Ki-67, COX-2 and HSP90. The expression patterns of the proteins 
were correlated to pathomorphological properties of the tumours as well as clinical 
parameters. Moreover, a presence of the BRAF gene mutation V600 has been analyzed 
in metastases from malignant melanomas. We found that melanocytic tumours are 
heterogeneous in respect to expression of the analyzed proteins as well as mutational 
status. Analysis of biomarkers and genetic aberrations might therefore be of importance 
for predicting the biological behaviour of the tumours. The results of the study are 
discussed in the light of eventual prognostic, diagnostic and therapeutic application of 
the analyzed proteins and mutational status. 
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1 BACKGROUND. 
 
 
1.1 Melanocytes and normal skin. 
 
Melanocytes are dendritic cells that derive from the neural crest and migrate into the 
epidermis as well as other epithelia (Kanitakis 2002). Depending on localization and 
the control mechanism regulating specific differentiation and melanin synthesis the 
melanocytes are divided in three major groups: cutaneous melanocytes, which 
continuously synthesize small melanosomes to be transferred to keratinocytes; the 
uveal melanocytes, which synthesize larger melanosomes for only a short while to be 
retained by this melanogenically dormant cell; and the hair melanocyte, which 
intermittently produces melanin either in a cyclic manner or as a periodic supply from a 
stem population(Boissy 1988). In the epidermis, the melanocytes are localized in the 
basal layer and their dendritic processes extend in all directions. The melanocytes are 
evenly distributed among basal keratinocytes at a ratio of 1 melanocyte per 4-10 basal 
keratinocytes. Their density reaches 500-2,000 cells per mm
2
 of cutaneous surface, with 
regional variations reaching maximal density on genital skin. Through the enzymatic 
activity of tyrosinase from the substrate tyrosine, melanocytes produce pigment 
melanin. To produce melanin, the MC1R (melanocortin-1 receptor) pathway is 
activated by the ligand alpha-Melanocyte Stimulating Hormone (α-MSH) binding to 
and stimulating the MC1R on the outside surface of the melanocyte (Figure)(Luger et 
al. 1997). Approximately 1000 of MC1R receptors exist on each normal melanocyte. 
 Two types of melanin are known: pheomelanin (red) and eumelanin (yellow-
black)(Quevedo 1979). The synthesis of melanin takes place in melanosomes, which at 
the early stages of development are membrane-limited vesicles located in the Golgi-
associated endoplasmic reticulum. The developing melanosomes, with their content of 
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melanin, are transferred to the neighbouring basal cells and hair follicular cells. The 
melanin transfers to keratinocytes by phagocytosis of the tips of the melanocytic 
dendrites in a process called pigment donation(Wolff 1973). In the adjacent 
keratinocytes the melanin pigment forms an umbrella-like cap over the nucleus, 
protecting it from injurious effects of UV light. 
 
Function on melanocytes in the normal skin.  
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1.2 Benign melanocytic tumours.  
In analogy with tumours of other origins, melanocytic neoplasias are grossly divided in 
two major groups: benign and malignant. Benign tumours, in turn, are divided in 
several subgroups depending on: 
1) Extension of tumour growth:   
- Intraepidermal/Superficial type, confined to basal membrane and epidermis 
(pigmented macules/freckles, Café-au-lait macules (CALMs), solar lentigo, 
Becker’s melanosis). 
- Junctional nevi (JN), the cells are confined to the dermoepidermal junction but 
in contrast to superficial type where cells are mostly organized in a single layer 
at the basal membrane, JN have a tendency to build nests of proliferating 
melanocytes, sometimes extending to the upper half of reticular dermis. 
- Compound nevi – melanocytic benign tumours where both epidermal and 
dermal components can be appreciated. 
- Intradermal nevi – tumours confined to the dermis.  
2) Genesis: congenital and acquired nevi. 
3) Cell morphology: small round cells, epithelioid, spindle cells, clear cells, 
balloon cells, polymorphic, dysplastic nevi, and nevi of mixed cellularity. 
4) Presence of stromal response, e.g. sclerosis and desmoplastic reaction (Spitz 
nevus, blue nevus)   
5) Anatomical site: skin, mucosal, acral, genital nevi.  
6) Presence of pigment: pigmented or amelanotic. 
Melanocytic nevi, in general, have an overall histologic symmetry and usually are well-
circumscribed(Ackerman 1982). The surface profile of a nevus may vary from being 
almost flat to dome shaped, polypoid or papillomatous(Rao et al. 2001). Existing 
classifications of benign melanocytic lesions are based on clinical and 
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histomorphological findings which not always reflect a complex nature of these lesions. 
The progress in our understanding of genetics, molecular events and pathways which 
lead to development of melanocytic lesions has stimulated attempts to extend the 
existing classification including evaluation of genes and molecules that are involved in 
melanogenesis(Bittner et al. 2000). It has been shown that gene signatures established 
using DNA microarray gene expression profiling can distinguish melanomas from nevi, 
indicating the feasibility of using molecular classification as a supplement to standard 
histology (Koh et al. 2009).   
           
1.3 Malignant melanoma 
Cutaneous melanoma is a malignant tumour that arises from skin pigmented cells – 
melanocytes. In most of the cases melanoma arise either via de novo proliferation of 
basal epidermal melanocytes, (Ackerman 1980), or as transformation of pre-existed 
benign nevi (Gruber et al. 1989; Holman et al. 1983). Depending on clinico-
histopathological properties of the tumour malignant melanomas are divided into four 
main types(Barnhill and Mihm 1993): 
1- Superficial spreading malignant melanoma (pagetoid melanoma) 
2- Nodular malignant melanoma 
3- Lentigo maligna melanoma 
4- Acral lentiginous malignant melanoma. 
Superficial spreading melanoma (SSM) is the most common type of cutaneous 
melanomas and accounts for approximately 70% of all primary tumours (MacKie 
2000). This type of melanoma usually originates in a pre-existing nevus and has a 
tendency for slow growth. The common sites for superficial spreading melanoma are 
the female leg and the male back which suggest that both intermittent and chronic UV 
exposure may be important initiating and/or promoting events. Patients are often in the 
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fourth or fifth decade at presentation(MacKie 2000). A remarkable morphologic feature 
of SSM is the presence of pagetoid spread – trans/intradermal migration of melanoma 
cells(Clark et al. 1984). Typical melanoma cell in SSM have an epithelioid appearance, 
with abundant, usually granular/eosinophilic cytoplasm, containing finely divided 
melanin. 
Nodular melanomas (NM) is the second most common type of melanoma, accounting 
for approximately 10-15% of all melanomas (Langley and Sober 1998). The main 
feature of the NM is a rapidly expanding nodular lesion often without history of a pre-
existing nevus(Barnhill and Mihm 1993). It is commonly seen on trunk and head /neck 
region(Lens 2008). Nodular melanomas present as rapidly growing protuberant or 
polypoid blue-black lesions, with much of the pigmentation being due to blood rather 
than to melanin. Ulceration is frequently present. A subset of NM lacks pigment and 
presents as a pink (amelanotic) tumour. The tumour cells most frequently are of 
epithelioid type, but other cell types may predominate, such as spindle cells 
multinucleate cells or even a mixture of the various types (Clark et al. 1986). The 
surrounding stroma often demonstrates variable degree of mononuclear cell infiltrates 
and accumulation of macrophages.  
Lentigo malignant melanoma (LMM) accounts for approximately 5-10% of all 
melanomas (MacKie 2000). It is mostly diagnosed in elderly people, with a peak 
incidence in the seventh decade (Langley and Sober 1998). The risk for development of 
LMM is strongly associated with a long-term cumulative sun exposure (Cohen 1995) 
which reflects that typical sites of development of LMM are the face (particularly 
cheeks and nose) and the neck. Lentigo maligna melanomas have a well identified 
slowly evolving radial growth phase known as lentigo maligna or Hutchinson's 
melanotic freckle. Over time a proportion of LMM will progress to invasive lentigo 
maligna melanoma, characterized by an invasive nodule developing within the pre-
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existing lentigo maligna(MacKie 2000).  Histologically, LMM is characterized by 
increased number of basal melanocytes with a variable, low-grade cytological atypia. A 
contiguous and often nested intraepidermal proliferation of pleomorfic melanocytes 
may occur. In addition, LMM is characterized by atrophy, effacement of the epidermis, 
involvement of skin appendages and solar elastosis(Clark and Mihm 1969).  
Acral lentiginous melanoma (ALM) represents approximately 2-8% of all 
melanomas(Barnhill and Mihm 1993). However, this type is the most common among 
dark-skinned population with a relatively low incidence of other melanoma types 
(Africans, Asians and Hispanics) where it may account for 30-70% of all melanomas 
(Cress and Holly 1997). Acral melanoma usually occurs in older patients on palms and 
soles with feet/hand ratio being approximately 8:1 (MacKie 2000).  Acral melanoma 
presents with features very similar to those of superficial spreading melanoma, but 
modified due to the thicker epidermis and stratum corneum of palmar or plantar skin. 
The lesions are usually heavily pigmented within an irregular outer margin and 
variegated central pigmentation and are often ulcerated at the time of diagnosis. 
Amelanotic variants of acral lentiginous melanoma do occur. A distinct variant of ALM 
that arises in the nail bed is named subunqual melanoma. The peak incidence of this 
type of acral lentiginous melanoma is in the seventh decade. These lesions are more 
commonly seen on the big toe or the thumb than on the other digits, and present with 
irregular pigmentation under and around the nail. A striking and strongly suggestive 
clinical feature is the presence of Hutchinson's sign: the presence at the proximal nail 
fold margin of an area of visible melanin pigmentation which is not seen in association 
with other causes of subunqual pigmentation such as a traumatic haemorrhage. The 
tumour is most often composed by spindle type melanocytes and may exhibit bone 
invasion and a prominent fibrovascular stromal response(Patterson and Helwig 1980).  
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Mucosal melanomas are rare melanomas comprising 2.2% of all melanoma 
cases(Patrick et al. 2007). Mucosal melanoma is most common in the head and neck 
region (hard palate, tongue and nasal mucosa) where it comprises 55.4% of all mucosal 
melanomas. The female genital tract, anorectal region and urinary tract are responsible 
for 18.0, 23.8% and 2.8% of mucosal melanoma cases, respectively (Chang et al. 
1998). The peak age for diagnosis of mucosal melanoma is between 70 and 79 years.   
 Like other cancers, most malignant melanomas evolve through several stages of 
tumour progression. Clinically, many melanomas begin as a pigmented patch of skin 
which evolves to become a palpable plaque with varying degree of pigmentation. This 
stage of melanoma progression has been termed the “radial growth phase” (RGP) 
which is divided in intraepidermal melanoma (melanoma in situ) and microinvasive 
melanoma. The duration of the intraepidermal phase may vary from several months to 
many years. A set of characteristic cytological and architectural changes is observed 
during this phase: proliferation of basal melanocytes with foci of confluence and 
upward migration of melanocytes expressing increasing cytological atypia (pagetoid 
spread). Commonly, there is extension of these proliferations along zones of skin 
appendages. After a period of intraepidermal proliferation melanomas in situ invade the 
papillary dermis(Clark et al. 1984). There is evidence that at this stage melanocytes 
lack capacity for proliferative nodular growth and metastasis(Clark et al. 1989). 
Microinvasive melanoma features a host response in the papillary dermis in form of a 
dense cellular infiltrate of lymphocytes and monocytes in a perivascular or bandlike 
pattern. Subsequently, malignant melanoma progresses into a vertical growth phase 
(VPG) which is characterized by the focal proliferation of melanoma cells as cohesive 
aggregates in the dermis. It has been postulated that progression of melanoma in to a 
vertical growth phase signals the onset of the metastatic phenotype(Clark et al. 1989). 
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Depending on invasion depth, melanomas are categorized into five groups named as 
Clark’s levels(Clark et al. 1969): 
1- Level I: confined to the epidermis (top-most layer of skin); called "in situ" 
melanoma 
2- Level II: invasion of the papillary (upper) dermis 
3- Level III: filling of the papillary dermis, but no extension in to the reticular 
(lower) dermis 
4- Level IV: invasion of the reticular dermis 
5- Level V: invasion of the deep, subcutaneous tissue 
Invasion depth in millimetres reported as Breslow’s invasion depth (Breslow 1970).  
 
 Clark’s invasion level and tumour thickness in relation to survival rate in 
melanomas. 
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1.3.1 Epidemiology of malignant melanoma 
Cutaneous malignant melanoma is one of the most rapidly increasing cancers in the 
white population worldwide (Diepgen and Mahler 2002; Lens and Dawes 2004) and as 
a consequence the increase in incidence of melanomas represents a significant and 
growing public health problem. The frequency of malignant melanoma is closely 
associated with the constitutive colour of the skin and also depends on the geographical 
zone. The highest incidence of melanoma in the world has been reported from New 
Zealand, Auckland, with an incidence of 77.7 per 100 000 and an age standardized 
annual rate of 56.2 per 100 000 with no statistical differences between males and 
females (Jones et al. 1999). High incidence rates have been reported also from 
Australia with 56 new cases per year per 100,000 for men and 43 for women in 1992 
(MacLennan et al. 1992). The rates of malignant melanomas in other countries are 
depicted in Table. The incidence of malignant melanoma in Sweden was 17.1 per 
100 000 in males and 15.5 per 100 000 in females during period 1990-1999 (Lindholm 
et al. 2004). It is noteworthy that incidence of cutaneous melanomas in Sweden in 
patients aged between 12-19 years doubled in 1983-1992 as compared to 1973-1982 
(Karlsson et al. 1998). A 5-fold increase of the melanoma incidence in Sweden was 
observed between 1960 and 2000. The estimated lifetime melanoma risk in Sweden for 
2006 was 1 in 50 at age 85 years (Karlsson and Fredrikson 2007). A 2.5-fold increase 
in melanoma incidence between 1970-1997 was observed in Finland and 3.6-fold 
increase in White Americans(Parkin and Iscovich 1997). From 1979 until 1998, a 2.4-
fold increase was observed in Scotland (MacKie et al. 2002) and from 1980 until 2000, 
2.8-fold increase was reported from France(Remontet et al. 2003). A study evaluating 
the incidence of malignant melanoma in situ in Sweden in 1968-1992 demonstrated 
that among men, the age-standardized rates increased from 0.1 per 100 000 in 1968 to 
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2.9 per 100 000 in 1992 with a mean annual increase of 15%(Thorn et al. 1992). The 
rates among women increased from 0.3 to 3.7 per 100 000 with mean annual increase 
of 12.8%.  
The number of deaths caused by cutaneous malignant melanoma has been increasing in 
most fair-skinned populations throughout the world(Diepgen and Mahler 2002). 
Between the mid-1950s and mid-1980s, the mortality rates from malignant melanomas 
have been increasing in both young (20-44years) and middle-aged (45-64 years) adults 
in most European countries(Franceschi and Cristofolini 1992) as well as North 
America, Australia and New Zealand with annual increase of 2-4% (La Vecchia et al. 
1999). Cohort analysis of age-specific rates shows a difference between older and 
younger cohorts in same countries. In cohorts aged 60 years and over the mortality 
rates have continued to increase in paste decades, while younger cohorts, particularly 
those born in 1960s and 1970s, the mortality rates have stabilized or even begun to 
decrease in North America, Scotland, Australia and several European countries(Marks 
2000). However, in France and Italy the mortality rate is still increasing (Severi et al. 
2000). The 5-year survival rate for males with malignant melanoma in Sweden 
increased from 54.5% in 1960-1964 to 73.1% in 1980-1982. The corresponding rates 
for females were 65.8% and 84.9%, respectively(Thorn et al. 1989). A further increase 
in relative survival rate in patients with malignant melanomas in Sweden to 88% in 
males and to 94% in females was reported between 1990 and 1999 (Lindholm et al. 
2004). 
Summarizing the above it can be concluded that malignant melanomas represent a 
major health problem in most western countries and it should be of high concern for 
both public and professional educational programmes to control it.  
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Incidence of cutaneous malignant melanoma (per 100 000) 
Country 
Male Female 
Crude ASR Crude ASR 
Australia 51·6 40·5 40·7 31·8 
New Zealand 45·2 36·7 44·4 34·9 
Sweden 19·8 12·6 19·9 13·3 
U.S.A. 16·4 13·3 12·9 9·4 
Denmark 14·8 10·6 17·6 13·0 
Switzerland 12·5 9·3 15·0 11·1 
The Netherlands 12·2 9·4 16·7 12·9 
Austria 11·5 8·8 15·4 10·4 
Canada 10·6 8·2 10·6 8·0 
Hungary 10·3 7·6 10·3 6·8 
Israel 9·7 9·4 11·0 9·8 
Germany 9·3 6·5 11·4 7·1 
France 8·6 6·8 11·1 7·9 
U.K. 8·3 6·1 11·3 7·7 
Poland 6·6 5·6 8·6 6·7 
Italy 6·5 4·6 8·2 5·5 
Russian Federation 6·3 5·4 6·4 4·7 
Spain 4·0 2·8 6·8 4·5 
South Africa 3·8 6·4 3·6 4·8 
Brazil 2·9 3·5 2·0 2·2 
Greece 2·5 1·9 3·2 2·0 
Japan 0·63 0·40 0·49 0·29 
China 0·21 0·22 0·17 0·17 
ASR- age standardized rate.  
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1.3.2 Etiology and risk factors in malignant melanoma. 
There are no proven causes of melanoma so far, however approximately 5% of all 
invasive cutaneous melanomas occur in a familial setting with two or more close 
relatives affected. This observation indicates that, in a small minority of melanoma 
patients, low prevalence/high penetrance genes are involved. In addition, the typical 
phenotype of the melanoma patient, with pale Caucasian skin, red or blond hair and 
blue eyes indicates that high prevalence/low penetrance genes such as MC1R 
(melanocortin 1 receptor), CDKN2A and HERC2/OCA2 may interact with 
environmental factors (Ibarrola-Villava et al. 2010). Association of pigmentation gene 
variants ASIP and TYR with malignant melanoma has been demonstrated [2]. The 
major constitutional risk factor for melanoma is skin colour and type. Depending on 
skin type as proposed by Thomas Fitzpatrick (Table)(Astner and Anderson 2004), the 
skin types I and II are most likely to develop malignant melanomas, while incidence of 
this tumour in skin types V and IV is considerably lower(Evans et al. 1988) with more 
than 100-fold difference in theirs sensitivity to the harmful effects of ultraviolet 
radiation(Rees 2004).  
The presence of a large number of both common acquired and dysplastic naevi is a 
second major constitutional risk factor in fair-skinned people (Bliss et al. 1995). 
Moreover, data from both prospective clinical and cohort studies are also consistent 
with greatly increased risk of melanoma in individuals with dysplastic nevi. Xeroderma 
pigmentosum, a skin disorder of impaired ability to repair DNA following UV 
exposure/damage is associated with substantially increased risk of developing 
melanoma, particularly at young age(Jen et al. 2009). Among the major risk factors, 
intense episodes of burning sun exposure appear to be most significant for the 
development of malignant melanoma (Elwood and Gallagher 1998). However, a 
cumulative exposure to UV-radiation over the years may also contribute to the risk. 
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Studies of place of birth and residence during first decade of life report an increasing 
risk of melanoma in individuals in high-UV environment (Fears et al. 2002). There are 
data which show an interaction between chronic sun exposure and the type of 
melanoma that may subsequently develop. The lentigo maligna variety of melanoma, 
found most commonly on constantly exposed body sites as the face, is associated more 
with chronic occupational UV exposure than intermittent burning UV exposure 
episodes (Whiteman et al. 2003). The potential risk factor of using artificial UV sources 
has been investigated by several studies. A recent large meta-analysis study of sunbed 
use and melanoma has concluded that overall sunbed exposure does add to risk of 
developing melanoma(MacKie et al. 2002). Different melanoma incidence between 
males and females with prevalence of the latter has been reported (Brochez and 
Naeyaert 2000). This has led to a number of studies investigating the role of pregnancy, 
oral contraceptives and hormone replacement therapy as risk factors for malignant 
melanoma. Cumulative data from publications on these topics provide no evidence that 
pregnancy(Karagas et al. 2006), the use of oral contraceptives (Lea et al. 2007) or 
hormone replacement therapy (MacKie and Bray 2004) contribute to the risk of 
developing melanoma. However, it was proposed that patterns of behaviour may 
explain the higher rates of melanoma among young women than men.  Adolescent girls 
are more likely to sunbathe, to get sunburned, to want to tan, and to use tanning beds. 
The rate of sunburns and tanning bed use are of great concern, and may contribute to 
the rising incidence rates in young women(Tucker and Goldstein 2003). Several studies 
have shown the melanoma prevalence in the wealthier strata of society. It has been 
shown that incidence of melanoma is higher in a large income groups and other 
measures of affluence (Kirkpatrick et al. 1990; Lee and Strickland 1980). The greater 
opportunity for the recreational sun exposure and sunny holidays during winter time 
were suggested as a possible explanation to this relationship.  
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Several studies have focused on studying occupational risks for developing of 
melanomas. A higher incidence in airline crews, particularly pilots has been reported 
(Pukkala et al. 2002). In addition, a relationship between immunosuppression and risk 
of developing melanomas has been of concern in several studies. While a 1.6 to 2.5-
fold increased risk of the melanoma was found in one study(Dinh and Chong 2007), 
these results could not be confirmed by another study(Lindelof et al. 2000). Finally, a 
recent case-control study on use of non-steroidal anti-inflammatory agents showed a 
reduced risk of developing malignant melanoma(MacKie et al. 2009).   
Fitzpatrick's Skin phototypes. 
Phototype 
Sunburn & 
Tanning 
history 
(defines the 
phototype) 
Immediate 
pigment 
darkening 
Delayed 
tanning 
Constitutive 
colour 
(unexposed 
buttock skin) 
UV-A 
MED 
(mJ/cm
2
) 
UV-B 
MED 
(mJ/cm
2
) 
I 
Burns easily, 
never tans 
None (–) None (–) Ivory White 20–35 15–30 
II 
Burns easily, 
tans minimally 
with difficulty 
Weak ± (± 
to +) 
Minimal 
to weak (± 
to +) 
White 30–45 25–40 
III 
Burns 
moderately, 
tans 
moderately 
and uniformly 
Definite + Low + White 40–55 30–50 
IV 
Burns 
minimally, 
tans 
moderately 
and easily 
Moderate ++ 
Moderate 
++ 
Beige-Olive, 
Lightly tanned 
50–80 40–60 
V 
Rarely burns, 
tans profusely 
Intense 
(brown) +++ 
Strong, 
intense 
brown 
+++ 
Moderate 
brown or 
tanned 
70–100 60–90 
VI 
Never burns, 
tans profusely 
Intense (dark 
brown) +++ 
Strong, 
intense 
brown 
+++ 
Dark brown or 
black 
100 90–150 
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1.3.3 Therapy options and clinical course of malignant melanomas. 
 
In his lecture from 1939 which was published by British Medical Journal (1939) 
professor Grey Turner described a case of a malignant melanoma in a 45 years old man 
who “had a black patch on the back, just below the angle of the scapula on the right 
side. It began to grow rapidly, and, two months before he himself saw the patient, was 
removed by his medical man. He was then discovered to have a melanotic tumour and 
a large mass of glands in the right axilla. The tumour was removed, with a reasonable 
amount of skin, and glands dissected out. A month later the black patch has recurred; 
there was a nodule at a little distance, and a mass of glands in the left axilla. Again the 
patch and the glands were removed, but in a very short time another nodule appeared 
and grew rapidly, enlarging in a few days from size of a sixpence to that of shilling. 
The patient died within seven months of the first interference with his melanotic grow”. 
Professor Grey had reported several clinical cases of malignant melanoma and in all 
patients “the story of treatment was on whole a melancholy one” which shows a highly 
malignant nature of this tumour. The situation described for almost a century ago is still 
highly actual. Despite the survival experience in stage IV melanoma patients has 
improved since 1985, the use of varied approaches to treat this disease has not 
produced a favourable long-term prognosis with estimated survival to be as low as 
13.6%, 9.7% and 2.3% for 2, 3 and 5 years, respectively(Lee et al. 2000). While 
approximately 75% of patients with stage I melanoma can be cured with surgery, stage 
IV melanomas are considered incurable by currently available therapies(Wagner et al. 
2000). Adjuvant therapy has not been particularly useful in such patients. Single-agent 
chemotherapy (Dacarbazine (DTIC)) and/or immunotherapies (either interleukin or 
interferon) remain the therapy of choice with a response rate of 16%.  Patients with 
metastatic melanoma at stage III and IV generally do poorly and have a median 
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survival of 4 to 6 months(Atallah and Flaherty 2005). Such patients are treated with 
systemic therapy unless they have a surgically resectable single site of metastasis, in 
which case the surgical resection is rather of a palliative character. Generally, survival 
worsens from non-visceral to visceral sites. Medial survival drops from 15 to 4 months 
as metastases involve skin/subcutaneous tissue, lung, liver/spleen/adrenal and 
brain(Essner et al. 2004). Survival is also related to the number of metastases. Median 
survival for involvement of a single site is approximately 7 months and decreases to 
less than 4 months for metastases with two or more sites(Young et al. 2006).  This 
illustrates the need of development of new therapeutic modalities in patients with 
advanced melanomas. 
For the melanoma patients with disease at stage I and stage II the surgical excision 
remain the treatment of choice where tumour thickness dictates the appropriate 
excisional margins. Wide excision of primary tumours with a normal skin margin of 0.5 
cm for in situ melanomas, of 1 cm for tumours with a Breslow thickness up to 2 mm 
and 2 cm for thicker tumours is recommended (Thompson et al. 2005). Sentinel lymph 
node biopsy in melanoma with a tumour thickness of >1 mm provides more accurate 
staging information, particularly for lesions of intermediate thickness (1–4 mm) but has 
no therapeutic value as it did not result in overall survival benefits. It may be followed 
by complete clearance of regional lymph nodes if the sentinel node was positive for 
micro metastases. However, this procedure has no proven effect on overall survival 
(Morton et al. 2006). Adjuvant immunotherapy with interferon-α at this stage might 
lead to a prolongation of disease-free survival. A study has demonstrated a positive 
effect on disease-free and distant metastases-free survival in patients with 
micrometastases (Eggermont et al. 2008). 
At the stage of locoregional (stage III) tumour, surgery remains a main therapeutical 
option. Removal of the primary tumour, and regional metastases including the 
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surrounding lymph node region, is indicated (Dummer et al. 2009). Adjuvant therapy 
with interferon and interleukin might be used at this stage.  
The current options in therapy of the stage IV advanced melanoma is of a palliative 
type. The use of tolerated single-agent cytotoxic chemotherapy such as dacarbazine, 
temozolomide or in combination with cytokines is used. However, such therapies do 
not result in survival prolongation and is used for symptom palliation only (Huncharek 
et al. 2001; Verma et al. 2008). In the absence of active biologic and chemotherapeutic 
agent for systemic melanoma, a surgery removal of visceral metastases may be 
appropriate for selected cases (Young et al. 2006). Surgery of advanced melanoma is 
most effective in patients exhibiting tumour which is limited to a few sites. Several 
retrospective studies on such patients have reported long-term survival, in some cases 
beyond 5 or 10 years, despite being initially considered incurable (Allen and Coit 2002; 
Allen et al. 2002; Essner 2003). Adjuvant radiotherapy has been shown to have a good 
regional control in some cases of metastatic melanomas and is highly depending on 
anatomical and pathological features of the tumour(Bibault et al. 2011). 
An adoptive cell therapy in patients with advanced melanoma is currently being 
evaluated. Adoptive T cell therapy (ACT) consists of isolating tumour reactive 
lymphocytes from a patient, growing and activating them in the laboratory, and 
infusing them back into the autologous patient(Rosenberg et al. 2008). Effectiveness of 
the ACT therapy in patients with  metastatic refractory melanoma has been recently 
demonstrated in one study (Dudley 2011).   
Advances in our understanding of the genetic and molecular events that control genesis, 
cell division, invasion, metastasis, evasion of immune surveillance and resistance to 
chemotherapy in malignant melanomas have led to production of antagonists for 
critical molecules which are involved in these processes (table). These substances are 
currently under estimation for specific targeted therapy in several studies (reviewed by 
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C. Garbe (Garbe et al. 2011)) giving us a sense of optimism for improvement in the 
outcome for patients with advanced melanomas. 
   
Targeted therapies under evaluation  
Drug Target 
Sorafenib RAF, VEGF-R, PDGR-R 
Bortezomib Proteasome inhibitor 
MS-275 Histone deacetylase inhibition 
Thalidomide Anti-angiogenic, immunomodulatory 
Revemid (CC5013) Anti-angiogenic, immunomodulatory 
Vitaxin (MEDI 522) vβ3 integrin mAb 
CNTO95 v integrin mAb 
Oblimersen bcl-2 antisense 
XIAP XIAP antisense 
Semaxanib (SU5416) VEGF-R2, kit 
Bevacizumab VEGF-R mAb 
 
  
 
1.3.4 The genes and molecular genetics of malignant melanoma. 
 
During the past decade a significant progress has been made in understanding of the 
genetics in melanocytic lesions. A  family history of malignant melanoma is one of the 
most significant risk factors for developing this tumour(Tucker and Goldstein 2003). 
Understanding of genotype correlations in these patients may lead to improved 
diagnostic and prognostic information for early detection and application of tailored 
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therapies for all melanoma patients. Three high-penetrance and one low-penetrance 
melanoma-predisposing genes have been identified and characterized. 
 
Melanoma-predisposing genes.   
 
 
The best-characterized high-penetrance gene locus is mapped to chromosome 9p21 
(Cannon-Albright et al. 1992) which encodes two distinct melanoma predisposition 
genes, cyclin-dependent kinase inhibitor 2A (CDKN2A, also called p16, or inhibitor of 
cyclin-dependent kinase 4A, INK4a) and ARF or p14. Germline mutations in one or 
both of these genes are associated with familial melanoma. The principal action of p16/ 
CDKN2A is to regulate G1-S passage by inhibiting CDK-4/6 kinases phosphorylation 
of the retinoblastoma protein. Overexpression of the p16/ CDKN2A results in G1 arrest 
in cells with inactive retinoblastoma protein(Serrano et al. 1996). P14/ARF acts via the 
p53-pathway to induce cell cycle arrest in response to hyperproliferative oncogenic 
signals (Gallagher et al. 2005). The third high-penetrance melanoma predisposition 
gene, cyclin-dependent kinase 4 (CDK4), is located on 12q13(Zuo et al. 1996). 
Mutation of this gene abrogate the capacity for p16/ CDKN2A to associate with and 
inactivate CDK4, resulting in a similar effect which is seen in cases with p16/ 
CDKN2A mutation(Hayward 2003). Since the activities of CDK4 and p16 both affect 
the same downstream effector, the retinoblastoma protein, it has been shown that 
clinical characteristics such as mean age of diagnosis of melanoma, mean number of 
melanomas and number of nevi are indistinguishable between CDKN2A mutation-
positive and CDK4 mutation-positive families(Goldstein et al. 2000). The likelihood of 
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finding mutation in CDKNA2 is dependent on the number of affected family members 
overall, rising from 5% in families with two affected members, to 20-40% in families 
with three or more affected, to 100% in families with 13 or more affected (Stahl et al. 
2004).    
In contrast to above mentioned high-penetrance genes, the MC1R, melanocortin 
receptor gene, is a low-penetrance gene located on chromosome 16q24.3 (Palmer et al. 
2000). Melanocortin-1 receptor plays a critical role in determining the type of melanin 
produced by melanocytes: eumelanin and pheomelanin (Scherer and Kumar 2010). The 
balance of red/yellow pheomelanin and black/brown eumelanin produced by activation 
of the receptor provides the basis for variation in skin pigmentation among 
humans(Rouzaud and Hearing 2005). The molecular mechanism contributing to the 
increased risk is that non-functional MC1R reduces the capacity of melanocytes to 
repair DNA damage from ultraviolet radiation (Rouzaud et al. 2005). More than 65 
MC1R variants have been identified and confer an increased (2.2-fold) risk for 
melanoma, making MC1R a low-penetrance predisposition gene [9]. In p16/ARF 
mutation carriers who inherit an MC1R variant, penetrance increased from 50% to 84% 
and the mean age of melanoma onset decreased from 58.1 to 37.8 years. Thus, MC1R 
appears to be both an independent low-penetrance predisposition melanoma gene and 
also a modifier gene in p16/ARF pedigrees. Moreover, the association of MC1R 
mutations and somatic BRAF/NRAS mutations results in a crucial for melanomas 
development mitogen-activated protein kinase (MAPK) (Scherer et al. 2010).  
Mutations of several oncogenic involved in essential pathways for melanoma 
development have been shown in several studies. Mutations of NRAS and BRAF genes 
which are involved in mitogen-activated protein kinase (MAPK) pathway have been 
identified in about 15% and 66% of malignant melanomas, respectively [15, 16]. 
NRAS and BRAF mutations are mutually exclusive, thus accounting for the MAPK 
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pathway activation in more that 80% of melanomas. Another pathway which is often 
activated in malignant melanomas is a Phosphatidylinositol 3-kinase (PI3K) pathway. 
PTEN (phosphatase and tensin homolog deleted in from chromosome ten) is a protein 
and lipid phosphatase that inhibits Akt activations by PI3K. Akt, in turn, is a 
serine/threonine kinase that leads to stimulation of cell cycle progression, cell 
proliferation, and inhibition of apoptosis (Dai et al. 2005). The mutations in the region 
of chromosome 10q24 which harbours the PTEN and impair its function locus was 
demonstrated in up to 50% of melanomas(Takata and Saida 2006). Moreover, the 
overexpression of Akt protein increases dramatically with melanoma invasion and 
metastasis and is inversely correlated with patient survival (Dai et al. 2005).  
Recently, amplification of the microphtalmia-associated transcriptional factor (MITF) 
gene was demonstrated in 10% of primary melanomas and 20% of metastatic 
melanomas, suggesting that MITF is a melanoma oncogene(Levy et al. 2006). MITF 
acts as a master regulator of melanocyte development, function and survival by 
modulating various differentiation and cell-cycle progression genes (Widlund and 
Fisher 2003).  
Thus, assessment of genetic status of malignant melanomas might dramatically 
contribute to our knowledge of melanoma genesis and progression and insight in 
development of novel therapeutic tactics pointed at critical events in the cascades of 
melanoma pathways.        
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1.3.5 Pathology of malignant melanoma. 
Patients with primary cutaneous melanocytic lesions rely not only on the knowledge, 
skill and experience of their physician but also on the important input of the pathologist 
who is responsible for an accurate diagnosis which is the basis for appropriate 
therapeutical management. However, the patient’s prognosis and further therapy are 
dependent not only on the pathologic diagnosis alone but also on other crucial 
pathologically assessed parameters: tumour thickness, Clark’s level of invasion, 
ulcerative state, inflammatory response and proximity to the resection margins. 
However, it is not always possible to accurately predict the melanoma prognosis purely 
from the histopathologic assessment which makes an inclusion of the molecular and 
genetic status of the analysed tumour a desirable option.   
In 1998, the American Joint Committee on Cancer (AJCC) Melanoma Staging 
Committee developed the AJCC melanoma staging database, an international 
integrated compilation of prospectively accumulated melanoma outcome data from 
several centres and clinical trial cooperative groups. Analysis of this database resulted 
in major revisions to the TNM staging system reflected in the sixth edition of the AJCC 
Cancer Staging Manual published in 2002(Kim et al. 2002). More recently, the 
committee's analysis of an updated melanoma staging database, including prospective 
data on more than 50,000 patients, led to staging revisions adopted in the seventh 
edition of the AJCC Cancer Staging Manual published in 2009(Balch et al. 2009). 
Generally, the classification and staging manual implicates the use of pathohistological 
and clinical criteria to stratify the melanoma patients to groups which differ in terms of 
tumour stage, thus demanding an individualized therapeutic approach. 
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TNM Staging Categories for Cutaneous Melanoma 
Classification Thickness (mm) Ulceration Status/Mitoses 
T   
Tis NA NA 
T1 ≤ 1.00 
a: Without ulceration and mitosis < 1/mm
2
 
b: With ulceration or mitoses ≥ 1/mm2 
T2 1.01-2.00 a: Without ulceration 
  b: With ulceration 
T3 2.01-4.00 a: Without ulceration 
  b: With ulceration 
T4 > 4.00 a: Without ulceration 
  b: With ulceration 
N No. of Metastatic Nodes Nodal Metastatic Burden 
N0 
0 NA 
N1 
1 a: Micrometastasis
*
 
  b: Macrometastasis
†
 
N2 
2-3 a: Micrometastasis
*
 
  b: Macrometastasis
†
 
  
c: In transit metastases/satellites 
without metastatic nodes 
N3 
4+ metastatic nodes, or matted nodes, or in 
transit metastases/satellites with metastatic 
nodes 
 
M Site Serum LDH 
M0 No distant metastases NA 
M1a Distant skin, subcutaneous, or nodal metastases Normal 
M1b Lung metastases Normal 
M1c All other visceral metastases Normal 
 Any distant metastasis Elevated 
Abbreviations: NA, not applicable; LDH, lactate dehydrogenase. 
*
Micrometastases are diagnosed after sentinel lymph node biopsy. 
†
Macrometastases are defined as clinically detectable nodal metastases confirmed 
pathologically. 
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Anatomic Stage Groupings for Cutaneous Melanoma. 
 
Clinical Staging
*
  
  
Pathologic Staging
†
  
 
T N M T N M 
0 Tis N0 M0 0 Tis N0 M0 
IA T1a N0 M0 IA T1a N0 M0 
IB T1b N0 M0 IB T1b N0 M0 
 T2a N0 M0  T2a N0 M0 
IIA T2b N0 M0 IIA T2b N0 M0 
 T3a N0 M0  T3a N0 M0 
IIB T3b N0 M0 IIB T3b N0 M0 
 T4a N0 M0  T4a N0 M0 
IIC T4b N0 M0 IIC T4b N0 M0 
III Any T N > N0 M0 IIIA T1-4a N1a M0 
     T1-4a N2a M0 
    IIIB T1-4b N1a M0 
     T1-4b N2a M0 
     T1-4a N1b M0 
     T1-4a N2b M0 
     T1-4a N2c M0 
    IIIC T1-4b N1b M0 
     T1-4b N2b M0 
     T1-4b N2c M0 
     Any T N3 M0 
IV Any T Any N M1 IV Any T Any N M1 
*
Clinical staging includes microstaging of the primary melanoma and clinical/radiologic evaluation for 
metastases. By convention, it should be used after complete excision of the primary melanoma with 
clinical assessment for regional and distant metastases. 
†
Pathologic staging includes microstaging of the primary melanoma and pathologic information about the 
regional lymph nodes after partial (ie, sentinel node biopsy) or complete lymphadenectomy. Pathologic 
stage 0 or stage IA patients are the exception; they do not require pathologic evaluation of their lymph 
nodes. 
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The pathology report on a primary cutaneous melanoma serves as ground source for 
melanoma staging and classification. The following histopathological features that 
affect prognosis and management of the melanoma patient are recommended for 
inclusion in the pathology report(Scolyer et al. 2004): 
1) Site of the tumour 
2) Diagnosis 
3) Histologic type 
4) Breslow Thickness 
5) Ulceration 
6) Dermal mitotic rate (per mm2) 
7) Clark’s level 
8) Vascular or lymphatic invasion 
9) Neurotropism 
10) Desmoplasia 
11) Satellites 
12) Features of regression 
13) Predominant cell type 
14) Associated nevus 
15) Nearest lateral and deep margin 
As immunohistochemistry and molecular biology has become a widely available and 
integral part of a modern pathology practice, the result of adjunctive 
immunohistochemical analyses as well as molecular analyses should preferably 
accompany the final pathology report.  
Another challenge in pathology practice is evaluation of sentinel nodes in patients with 
malignant melanomas. The sentinel lymphadenectomy procedure allows the regional 
lymph nodes of melanoma patients to be histopathologically staged without the need to 
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perform an elective complete lymph node dissection (Balch et al. 2001; Davids et al. 
2003). In this way only those patients with definite occult nodal involvement are 
exposed to a selective completion lymph node dissection and adjuvant 
therapy(Reintgen et al. 1997). Those patients who have no sentinel node metastases can 
be spared from undergoing unnecessary further surgery and/or adjuvant therapy and 
can also be reassured of a better prognosis. The use of histological, immunochemical 
and molecular techniques in evaluation of the sentinel nodes are constantly improving 
which may reduce the false negative pathology reports. 
Fine needle aspiration biopsy (FNAB) became a useful diagnostic modality for the 
assessment of palpable(Zajicek 1977) and non-palpable masses(Perry et al. 1986). It is 
particularly useful for visible or palpable masses occurring in melanoma patients that 
are clinically suspicious of recurrence of metastasis(Nasiell et al. 1991). CT- or 
ultrasound guidance allows fine needle aspiration and cytological diagnosis of non-
palpable melanoma metastases in a cost effective and time saving manner. 
Despite the fact that the clinical and pathological criteria distinguish most benign 
lesions from malignant ones are well recognized, occasionally difficulties in diagnosis 
occur, resulting in benign lesions being diagnosed as malignant and vice versa. The 
consequences of misdiagnosis may be disastrous. Benign nevi that are treated as 
melanomas may cause unnecessary disfigurement and morbidity, while melanomas 
misdiagnosed as nevi may result in delayed treatment and death of the patient.  
Therefore, the pathological diagnosis of malignant melanoma requires a thorough 
knowledge of its diagnostic features, pathogenesis and natural history as well as a keen 
awareness of potential diagnostic pitfalls. It is likely that future advances in 
understanding of the genetic and molecular basis of melanoma improve diagnostic 
accuracy and prognostic ability, which in turn will lead to the development of precisely 
targeted therapies.    
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1.3.6 Prognostic markers in malignant melanomas. 
1.3.6.1 S100 
The first member of the S100 protein family was originally isolated by Moore (Moore 
1965) as a protein fraction from bovine brain tissue. This protein fraction was named 
S100 due to its solubility in 100% saturated ammonium sulphate solution at neutral 
pH. S100 was purified from bovine brain and at that time believed to be brain specific. 
Since then expression of S100 proteins has been demonstrated in a diverse spectrum of 
tissues and a total of 25 forms of this protein have been isolated and described 
(Santamaria-Kisiel et al. 2006). Generally, an S-100 family is found exclusively in 
vertebrates and are small acidic proteins  with molecular weight ranging between 9 and 
13 kDa.(Schafer and Heizmann 1996). Twenty one S-100 family members (S100A1-
S100A18, trichhylin, filaggirin and repetin) have genes clustered at chromosome locus 
1q21, while other S-100 proteins are found at chromosome loci 4p16 (S100P), 5q14 
(S100Z), 21q22 (S100B) and Xp22 (S100G). All S-100 proteins, with the exception of 
S100G, exist as a symmetric dimmer, with each monomer containing two EF-hand 
motifs. The two EF hands are interconnected by an intermediate region, referred to as 
the hinge region. Each of EF-hand motifs characterized by presence of two Ca2+ 
binding sites of different affinity. S 100 members differ from one another mostly for 
the length and sequence of the hinge region and the C-terminal extension, which are 
therefore suggested to specify the biological activity of individual proteins (Donato 
2003) Three members of the S-100 family (profilaggrin, trychohyalin and repetin) are 
large proteins that exhibit an S100 motif along their primary sequence. S100 proteins 
have no known enzymatic function and exert their intracellular effects by interacting 
with and modulating the activity of other proteins. S100 proteins are proposed to have 
intracellular and extracellular roles in the regulation of many diverse processes such as 
regulation of cytoskeletal components, protein phosphorylation, cell growth and 
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motility, cell-cycle regulation, transcription differentiation and cell survival (Donato 
2001) Upon Ca2+ binding, each of S100 monomer opens up to accommodate a target 
protein. In this way, an S100 dimer functionally cross-bridges two homologous or 
heterologous target proteins. Specification of S100 protein interaction with target 
proteins depends on the amino acid sequence of the individual S100 regions 
participating in the formation of the binding site, differences in the orientation of 
helices in individual s100 proteins and structural characteristics of target proteins 
(Donato 2003) Currently more than 90 target proteins for activated S100 forms have 
been identified. The most significant number of S100 proteins has been shown to 
affect components of the cytoskeleton (S100B, S100A1, S100A2, S100A4, S100A6 
and S100A11). However several of S100 have been also implicated in a variety of 
signal-transduction pathways activating an intracellular signal cascade that contributes 
to cell proliferation and survival (S100B, S100A1, S10012 and WS100P) (Santamaria-
Kisiel et al. 2006) Some S100 members have been shown to regulate the activity of the 
same target molecules, often with different affinity. Several S100 family proteins have 
been demonstrated to play a role in development and progression of malignant tumours 
including those of melanocytic origin.  The present theses have been focused on 
expression of the S100A1 and S100B in melanocytic tumours. The first one, S100A1 
protein, has a molecular weight of 10.4kDa and exists as a homodimer of two S100A1 
molecules (Rohde et al. 2010) Dimerization of S100A1 occurs independently of Ca
2+
 
binding in a symmetric and antiparallel manner and is stabilized through hydrophobic 
bonds between helices. At present, more than twenty target proteins for S100A1 have 
been discovered (Wright et al. 2009). S100A1 exerts its function mainly as regulator of 
the dynamics of cytoskeleton constituents. However, having p53 and RAGE (receptor 
for advanced glycation end products) as target proteins S100A1 takes a part in 
inhibition of the cell repair as well as acts as growth factor. Involvement of S100A1 in 
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neoplastic disorders has been showed in several studies. Increasing levels of S100A1 
in endometrial and ovarian cancers have been revealed in one study (DeRycke et al. 
2009). Another study conducted by on renal neoplasms showed that S100A1 protein is 
expressed in oncocytomas, clear cell and papillary renal cell carcinomas but not in 
chromophobe renal cell carcinomas showing potential use of S100A1 staining for the 
differential diagnosis between chromophobe renal cell carcinoma and oncocytoma. 
(Rocca et al. 2007) Similar observation was reported by Li G and colleagues in study 
conducted on renal cancers (Li et al. 2007) Moreover, it has been shown that S100A1 
has a modulation effect on metastasis promoting activity of S100A4 protein in 
mammary cancer (Wang et al. 2005) Several studies have been focused on expression 
of S100A1 proteins in malignant melanocytic tumours. In one study the researchers 
found that S100A1 protein in not expressed in melanocytic lesions of benign and 
malignant character (Boni et al. 1997). However, a different expression pattern has 
been shown in a study conducted on conjuctival melanocytic lesions showed  high 
expression levels of S100A1 in malignant melanocytic lesions compared to benign 
(Keijser et al. 2006) which was confirmed by another study conducted on different 
subtypes of malignant melanomas (Nonaka et al. 2008) 
The second protein the present which theses have been focused on is a S100B protein. 
It has a mass of 21.5-kDa and shows structure of a symmetric homodimer. Among 
other target proteins S100B has been shown to modulate the activity of p53 in different 
ways. By protecting of p53 from thermal denaturation and aggregation S100B 
stimulates p53-dependent cell growth arrest and apoptosis, thereby exerting tumour-
suppressing activity. On contrary, by inhibiting of p53 transcription activation via 
disruption of the p53 tetramer the S100B protein exerts its tumour-promoting activity 
(Donato 2003) Several studies have been focused on analysis of the S100B expression 
in neoplastic disorders of different origin. A decreased expression of S100B protein 
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has been showed in bladder cancers (Yao et al. 2007). However, another study 
concluded that there no difference in S100B expression between renal cells cancer and 
normal kidney tissue, (Yang et al. 2004) Immunohistochemical analysis of S100B 
expression in colon cancer showed that this protein might be an independent predictor 
of early tumour relapse in II and III postoperative colon cancer patients stage (Hwang 
et al. 2011). Increased expression of S100B protein has been demonstrated in highly 
metastatic cell lines derived from lung cancer (Hu et al. 2010). A relation between 
increase of S100B protein expression and grade of malignancy in tumours of central 
nervous system has been reported (Camby et al. 1999). A number of studies have been 
focused on analysis of S100B expression in melanocytic tumours. Serum levels of 
S100B in patients with malignant melanomas have been extensively studied while, to 
our knowledge, only a few number of papers report expression of this protein in 
tumour cells. A variable expression pattern of this protein has been demonstrated. In a 
study conducted on conjunctival and uveal melanomas the authors reported an 
increased level of S100B in conjunctival melanomas while tumours of uveal origin 
showed a decrease of expression (Keijser et al. 2006). An expression analysis of 
S100B in cutaneous melanomas as well as normal melanocytes showed equally high 
levels in melanocytes, primary melanomas as well as metastatic tumours (Boni et al. 
1997).   ]. It has been shown that analysis of S100B in serum may be useful in 
identifying high-risk cases and monitoring the response to therapy in  patients with 
malignant melanoma (Hansson et al. 1997) as well as used as a independent prognostic 
factor (Bouwhuis et al. 2011).  
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1.3.6.2 CD44 
CD44 is a ubiquitous multistructural cells surface adhesion molecule involved in cell-
cell and cell-matrix interactions (Naor et al. 1997) and exerts its function as a principal 
receptor for hyaluronate (Aruffo et al. 1990). The CD44 gene has been mapped to the 
chromosomal locus 11p13 and is composed of two groups of exons. One group, 
comprising exons 1-5 and 16-20 are spliced together to form standard isoforms 
(CD44s). Another group, containing variable exons 6-15 (v1-10) can be alternatively 
spliced and inserted within the standard exons generating variants of CD44 
(CD44v)(Tolg et al. 1993). The standard CD44 protein isoform consists of three 
regions, a 72AA C-terminal cytoplasmic domain, a 21AA transmembrane domain and 
a 270AA extracellular domain (FIG) (Goodison et al. 1999). The variable region at 
which alternatively spliced variant are inserted is located in extracellular domain. The 
principal ligand for CD44 is hyaluronic acid (HA) which is a linear, polymeric 
glycosaminoglycan with at least three binding sites to CD44 molecule (Yang et al. 
1994). All CD44 isoforms contain the HA recognition sites, however, not all cells 
expressing CD44 bind the HA ligand constitutively. Cells can express CD44 protein in 
active, inducible and inactive state in respect to HA binding capability. Besides HA a 
number of extracellular ligangds such as osteopontin, collagen, fibronectin and laminin 
can bind to CD44 molecule (Goodison et al. 1999). The CD44s protein has multiple 
functions which explained by diversity of the CD44 variants. Primarily the standard 
variant of the CD44 is involved in the maintenance of three dimensional organ/tissue 
structure(Lesley et al. 1993). It has been shown that CD44 plays a critical role in 
angiogenesis, stimulating proliferation of endothelial cells (Trochon et al. 1996), 
wound healing (Jain et al. 1996), cell migration (Trochon et al. 1996), cells adhesion 
and aggregation (Green et al. 1988). Moreover, it has been shown that by interacting 
with HER2 cell surface protein the CD44 potentates invasiveness of tumour cells (Xu 
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et al. 1997). Involvement of the CD44 protein in neoplastic processes by diverse ways 
has been reported. Recently it has been found that the CD44 expression correlated with 
tumorigenicity in oesophageal squamous cell carcinomas (Zhao et al. 2011). Another 
study has summarized evidence of the CD44 involvement in ovarian cancer initiation, 
progression and intra-peritoneal spreading as well as distant metastasizing (Ween et al. 
2011). It has been reported that the CD44 protein involved in progression of prostate 
cancer (Ghatak et al. 2010; Iczkowski 2010), breast cancer (Bagnoli et al. 2010), 
neurofibroma (Riddle et al. 2010), glioblastomas (Xu et al. 2010) and colorectal 
cancers (Wan et al. 2009). Several studies confirmed the role of the CD44 molecule in 
progression and proliferation of malignant melanomas (Ahrens et al. 2001; Dietrich et 
al. 1997) High level of expression of CD44 protein in primary malignant melanomas 
have been associated with increased metastatic risk and reduced survival. Highly 
metastatic melanoma cell lines show increased expression of the CD44 compared to 
melanocytes and melanoma cell lines of low metastatic activity(Goebeler et al. 1996). 
Besides its prognostic importance, the CD44 protein may have a role in therapeutic 
strategies in malignant tumours including that of melanocytic origin. There is evidence 
that blocking of HA by soluble CD44s decrease proliferation of melanoma cells [22]. 
Another study shows that binding of the CD44 protein by anti-CD44 antibody inhibits 
melanoma cells proliferation (Ahrens et al. 2001). The expression of the CD44 protein 
in metastatic melanomas might have therefore a prognostic as well as therapeutic 
importance.   
 
 
 
 
                           
   33 
1.3.6.3 CD40 
CD40 is a cell surface receptor that belongs to the tumour necrosis factor-R (TNF-R) 
family and was first identified and functionally characterized on B lymphocytes (van 
Kooten and Banchereau 2000). It is a 45-50 kDa transmembrane glycoprotein and 
found on the surface of B lymphocytes, dendritic cells, follicular dendritic cells, 
haematopoietic progenitor cells, epithelial cells, and carcinomas (Banchereau et al. 
1994) The CD40 gene maps to human chromosome 20q11-2-q13-2.  The CD40 
molecule composed of 277AA with 193AA extracellular domain, a 22AA 
transmembrane domain and a 62AA intracellular tail. The ligand for CD40 (CD40L, 
CD154, TRAP) is a type II membrane protein with significant sequence homology to 
TNF is primarily expressed on activated CD4+ T but is also found on stimulated CD8+ 
T cells, mast cells, eosinophils, B cells and dendritic cells(Grewal and Flavell 1998). 
Contact dependent interaction of the CD40 with its ligand at the surface of helper T-
cells triggers the activation of protein tyrosine kinases, phosphoinositide-3 kinase and 
phospholipase resulting in rescue from apoptosis and growth and differentiation of B-
cells (Splawski et al. 1993) The demonstration of the critical role of CD40/CD40L 
interactions in vivo came from discovery that the hyper IgM syndrome, an X-linked 
immunodeficiency, is due to a genetic alteration of the CD40L gene located at the X 
chromosome(Notarangelo et al. 1996).  On non-haematopoietic non-neoplastic cells, 
the CD40 is involved in the amplification  and regulation of inflammatory responses 
(van Kooten and Banchereau 2000). A number of studies have shown that CD40 is also 
expressed in a majority of carcinomas including ovarian, nasopharyngeal, bladder and 
breast (Eliopoulos et al. 2000) as well as melanoma (von Leoprechting et al. 1999) 
Interestingly that CD40 ligation on the surface of many malignant tumours including 
that of melanocytic origin have an opposite effect to what was reported on normal 
haematopoietic cells and results in inhibition of proliferation, induction of apoptosis 
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and direct cytotoxic effect (Vonderheide 2007) Therefore, treatment of tumour cells 
with CD40L or homologous substances might have an important therapeutical 
implications. A number of studies have showed positive effect of CD40L treatment 
inhibiting growth of breast cancer (Hirano et al. 1999), B-lymphomas (Funakoshi et al. 
1994), ovarial cancer (Ghamande et al. 2001), myeloma (Tai et al. 2004), cervical 
cancer (Hill et al. 2005), mesothelioma (Friedlander et al. 2003) and melanomas (von 
Leoprechting et al. 1999). Moreover, expression of CD40 as well as CD40L by 
melanoma cells has been shown to be an independent prognostic marker(van den Oord 
et al. 1996). Thus, detection of CD40 molecule of the surface on metastatic melanoma 
cells might have therapeutic as well as prognostic implication.     
        
1.3.6.4 Bcl-2 
Bcl-2 is an acronym for the B-cell lymphoma/leukaemia-2 gene. The bcl-2 gene was 
first discovered because of its involvement in B-cell malignancies (Tsujimoto et al. 
1985) , where chromosomal translocation from its normal position at 18q21 into 
juxtaposition at 14q32 results in overproduction of bcl-2 mRNAs and their encoded 
proteins (Nowell et al. 1985) Bcl-2 is novel among proto-oncogenes in that its coded 
protein localizes in inner mitochondrial membrane (Hockenbery et al. 1990). It has 
been discovered that stable expression of bcl-2 permitted prolonged survival of 
immature pre-B-cells without concomitant cell proliferation (Vaux et al. 1988). Thus, it 
was suggested that bcl-2 plays a central role in apoptosis – an autonomous pathway of 
programmed cell death that helps restrict cells numbers, which is crucial during 
embryonic development, organogenesis and homeostasis (Wyllie 1987a; Wyllie 
1987b). A number of proteins which share structural and functional homology with its 
predecessor, bcl-2, have been discovered during last decades. The proteins comprise a 
bcl-2 family characterized by presence of at least one homology domain (BH). These 
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proteins are further divided into three subfamilies based on their function and structure. 
The anti-apoptotic members include Bcl-2, Bcl-XL, Mcl-1, Bcl-w and A1/Bfl1. The 
second subfamily has a pro-apoptotic function and includes Bax and Bak. The third 
subfamily is the BH3-only group, so named because their sequence homology with the 
rest of the family is restricted to the BH3 domain (FIG)(Leibowitz and Yu 2010). The 
BH3-only proteins are largely responsible for sensing the apoptotic signals and then 
transmitting them to other Bcl-2 family members (Huang and Strasser 2000). This 
degree of functional diversity allows for cell and tissue-specific regulation of apoptosis 
in response to a broad range of stress stimuli. Regardless of the pathway to activation of 
proapoptotic Bax and/or Bak, the end result is mitochondrial outer membrane 
permeabilization, leading to the release of several pro-apoptotic proteins, including 
cytochrome c, SMAC/DIABLO and AIF (FIG) The release of these proteins into the 
cytosol leads to activation of caspases that carry out the controlled demise of the cell, 
through cleavage of structural proteins, kinases, transcriptional proteins and others, all 
leading to cell death(Li and Yuan 2008). The Bcl-2 family of proteins is a common 
target for deregulation in cancer, with several anti-apoptotic members being 
overexpressed and pro-apoptotic members being mutated or silenced in a variety of 
tumour types (Yip and Reed 2008). A number of studies have focused on bcl-2 
expression in human malignancies showing different, sometimes controversial 
expression pattern of this protein. A increased expression of the bcl-2 has been 
associated with carcinogenesis and progression of prostate cancer (Catz and Johnson 
2003), while overexpression of this protein in breast cancer marks a good prognosis 
(Schorr et al. 1999). However another study concerning expression of bcl-2 in breast 
cancer reported that there is no significant association of bcl-2 expression with either 
overall survival or disease free survival (Cecka et al. 2008). Longer survival rates were 
reported in colon cancers overexpressing bcl-2 (Kouraklis et al. 2003; Meterissian et al. 
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2001). Further, association of the increased expression of bcl-2 and better prognosis 
was reported in renal carcinomas (Itoi et al. 2004), squamous carcinomas of head and 
neck region(Lo Muzio et al. 2005) and cervical cancer (Crawford et al. 1998). 
However, expression of bcl-2 has no or minimal prognostic impact in gastric (Muller et 
al. 1998) and ovarian(Berker et al. 2002) carcinomas. Expression of the bcl-2 in 
melanocytic tumour of benign as well as malignant type has been extensively studied. 
While normal melanocytes and benign pigmented nevi show strong bcl-2 expression, a 
decrease in bcl-2 expression in malignant melanomas has been reported (Radhi 1999; 
Saenz-Santamaria et al. 1994). A significantly shorter survival was documented in 
melanoma patients with increased expression of bcl-2 which suggesting the bcl-2 
measurement as a useful prognostic marker (Grover and Wilson 1996). However, other 
studies failed to show such a relationship and discovered that high bcl-2 expression in 
primary melanomas did not correlate with a worsening of prognosis and even reduced 
levels were found in melanoma metastases (Zhuang et al. 2007). Besides its possible 
prognostic value, detection of bcl-2 in cancers might have a therapeutic application. In 
the first place, a silencing method using antisense technology that in principle inhibits 
bcl-2 expression level by oligonucleotide G3130 showed promising results in several 
clinical trials of different cancers including malignant melanoma (Di Cresce and 
Koropatnick 2010; Moulder et al. 2008). Another approach is to block the activity of 
bcl-2 using antibodies directed against this protein. An intracellular anti-bcl-2 single 
chain antibody has been shown to increase drug-induced cytotoxicity in the breast 
cancer cell lines(Piche et al. 1998). Other approaches which use a blockade of bcl-2 
includes use of ribozymes and syntetic Bak HB3 peptide that binds to bcl-2 (Wang et 
al. 2000). Since a limited success has been showed using the blockage approach, 
different strategies, mainly focused on antagonizing the function of Bcl-2 rather 
inhibiting it are currently studied and might have application in therapy of malignant 
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melanoma (Azmi et al. 2011). It is therefore of high interest to estimate expression of 
Bcl-2 in metastatic malignant melanoma since both prognostic and therapeutic 
application of that knowledge may be of importance.     
     
1.3.6.5 Ki-67 
The Ki-67 was initially described as a monoclonal antibody which recognizes a nuclear 
antigen present in proliferating cells but absent in resting cells (Gerdes et al. 1983). 
These findings suggested that Ki-67 is directed against a nuclear antigen associated 
with cell proliferation. The gene encoding Ki-67 protein is localized in chromosome 10 
(Schonk et al. 1989)and consists of 15 exons which are transcribed to several splice 
variants including two forms detectable at protein level(Gerdes et al. 1991). It has been 
demonstrated that regulation of the Ki-67 protein during the cell cycle is associated 
with mitosis-specific phosphorylation (Endl and Gerdes 2000). Phosphorylation and 
dephosphorylation of the Ki-67 protein are controlled by key regulatory structures of 
the cell cycle and occur at two hallmark events within the cell cycle: the breakdown 
and the reorganization of the nucleus during mitosis(Endl and Gerdes 2000). This 
feature is extensively used in tumour diagnostics to estimate the growth fraction of a 
given cell population. The antibody against Ki-67 was used to assess the rate of 
proliferation virtually in all human malignancies providing valuable prognostic 
information as well as monitoring tumour response to established and trial therapies 
(Brown and Gatter 1990) Assessment of Ki-67 expression in melanocytic tumours of 
benign and malignant type is well documented. While benign melanocytic tumours 
show a low growth fraction, malignant melanomas and its metastases express high rates 
of Ki-67 protein expression (Bergman et al. 2001; Soyer 1991). Moreover, 
immunohistochemical assessment of Ki-67 may be used as a diagnostic tool and helps 
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distinguishing compound nevi of Spitz type from malignant melanomas(Kanter-
Lewensohn et al. 1997). 
 
 
 
1.3.6.6 CD117 
CD117 (KIT) is a 145-kDa transmembrane glycoprotein that is structurally related to 
the receptor for macrophage growth factor (CSF-1) and the receptor for platelet-deriver 
growth factor and belongs to group of tyrosine kinase receptors (Yarden et al. 1987). 
The CD117 protein is encoded by a KIT (in the literature and here the name KIT is 
used instead of the name c-kit for simplicity for both the protein and gene name; the 
context tells which one is meant) proto-oncogene which is widely expressed as a single 
transcript and has been mapped to chromosome 4q12.  The genomic DNA of KIT gene 
contains 21 exons (Vandenbark et al. 1992). The KIT protein consists of a extracellular, 
a transmembrane, a juxtamembrane and a intracellular split tyrosine kinase 
domains(FIG) (Pawson 2002). The Extracellular domain of the KIT protein contains 
five immunoglobulin-like loops which are encoded by exons 1-9. The transmembrane 
and the juxtamembrane domains are encoded by exons 10 and 11, respectively. Finally, 
the intracellular split tyrosine kinase domain is encoded by exons 13-21. The second 
immunoglobulin like loop of the extracellular portion of the CD117 protein binds to a 
ligand known as a stem-cell factor (SCF) (Williams et al. 1990) and is essential for 
development of melanocytes, erythrocytes, germ cells, mast cells and interstitial cells of 
Cajal (ICCs) (Huizinga et al. 1995; Maeda et al. 1992). SCF binding induces KIT 
dimerization and phosphorylation on tyrosines in the intracellular domain of the 
receptor. This then activates downstream protein targets such as mitogen-activated 
protein kinase (MAPK) in a cascade manner. The end results of KIT activation include 
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regulation of apoptosis, cell proliferation, differentiation, adhesion and motility 
(Miettinen and Lasota 2005; Ullrich and Schlessinger 1990). The significance of KIT in 
pathology of non-neoplastic diseases is illustrated by the consequences of its 
inactivating mutations leading to impairment of dependent cell types with macrocytic 
anaemia(Munugalavadla and Kapur 2005), mastocytosis(Longley et al. 1999), 
sterility(Huynh et al. 2002), and loss of skin pigmentation-piebaldism (Huynh et al. 
2002) and albinism(Giebel and Spritz 1992). On the contrary, gain-of-function KIT 
mutations lead to tumours of KIT-dependent cell types(Kitamura and Hirotab 2004). 
Activating mutations typically confer constitutional KIT phosphorylation and 
downstream activation independent of ligand binding. Detection of the KIT protein in 
human malignancies have been of great interest in respect to therapeutical, aetiological, 
diagnostic and prognostic prospective. A lot of studies have been focused on use of a 
tyrosine kinase blocking agent, imatinib mesylate, in gastro-intestinal stromal tumours 
(GIST). It was found to be highly effective against metastatic and unresectable tumours 
(Demetri et al. 2002). The response is best in tumours with exon 11 mutations. The 
response is moderate with exon 9 mutation and poor with exon 17 mutations (Heinrich 
et al. 2003). Encouraged by the therapeutic success in GISTs, several researchers have 
been studying the expression of KIT proteins in various human malignancies. Increased 
expression of KIT have been documented in mesenchymal tumours of uterus and ovary 
(Erdogan et al. 2007), ovarian cancer(O'Neill et al. 2005), small cell lung 
carcinoma(Lopez-Martin et al. 2007), colon cancer(Toyota et al. 1993), breast 
cancer(Eroglu and Sari 2007), pancreatic cancer(Yasuda et al. 2006) and acute 
leukaemia(Valverde et al. 1996). Expression of KIT protein in melanocytic lesions of 
benign and malignant type has been extensively studied. It has been shown that 
whereas benign melanocytic tumours frequently express KIT at high levels, a decrease 
of KIT expression is found in malignant melanomas(Ohashi et al. 1996). This 
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relationship was later confirmed by several studies (Huang et al. 1998; Montone et al. 
1997). However, some subtypes of malignant melanomas constitutively show high 
levels of KIT protein (All-Ericsson et al. 2004; Potti et al. 2003). It therefore can be 
speculated that malignant melanomas are heterogeneous tumour group in respect to 
expression of the KIT protein and detection of KIT-positive tumours might have 
diagnostic, prognostic and therapeutic importance.    
 
1.3.6.7 COX-2 
The enzyme cyclooxygenase (COX) also designated as prostaglandin H2 synthase 
(PGHS)  catalyzes the first step of the synthesis of prostanoids, including g 
prostaglandins, prostacyclin and tromboxane(Hinz and Brune 2002). It has been 
demonstrated that COX exist as two distinct isoforms: COX-1 and COX-2 (Fu et al. 
1990). COX-1 is located on chromosome regions 9q32-q33.3 and COX-2 maps to 
1q25.2-1q25.3 (Vane et al. 1998). COX-1 is constitutively expressed in most tissues as 
a “housekeeping” enzyme and appears to be responsible for the production of 
prostaglandins that mediates regulation of homeostatic functions throughout the 
body(Adelizzi 1999), such as the maintenance of the integrity of the gastric 
mucosa(Sakamoto 1998), normal platelet function and the regulation of the blood 
flow(Crofford 1997). In contrast, COX-2 is undetectable in most normal tissues but 
expressed by cells that are involved in chronic and acute inflammation (e.g., 
macrophages, monocytes, synoviocytes)(Hinz and Brune 2002). The existence of a 
third COX isoform, COX-3, with proposed anti-inflammatory function is currently 
discussed(Willoughby et al. 2000).    
The COX-2 may be induced by cytokines (interleukin), growth factors (TGF-B, 
transforming growth factor; EGF, epidermal growth factor), oncogenes and tumour 
promoters thereby contributing to the synthesis of prostaglandins in inflamed tissues 
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and malignant processes(Fosslien 2000). Most of the transcriptional signalling 
pathways require activation of the mitogen-activated protein kinase (MAPK) cascade. 
Moreover, MAPK signalling pathways are involved in regulating COX-2 gene 
expression at the post-transcriptional level(Tanabe and Tohnai 2002). Interestingly, the 
cyclooxygenase is irreversibly self-deactivating during the oxygenation of its substrate 
and therefore must be replaced to sustain production of prostaglandins(Fosslien 2000). 
In tumours, prostaglandins synthesised by COX-2 signal via receptors to stimulate 
cancer cell proliferation[10], inhibit apoptosis[9] and stimulate cancer cell 
motility(Singh et al. 2005), enhance cancer-induced angiogenesis(Toomey et al. 2009) 
and invasiveness(Chen et al. 2001).  Moreover, it has been demonstrated that COX-2 
may play a critical role in carcinogenesis of colorectal cancer(Wu et al. 2003), 
oesophageal squamous cells carcinomas[15], hepatocellular carcinoma(Ogunwobi and 
Liu 2011)and gastric carcinomas (Forones et al. 2008). Expression of COX-2 enzyme 
in melanocytic neoplasms of benign and malignant type has been demonstrated in 
several studies. The levels of COX-2 expression are significantly higher in melanomas 
compared to benign naevi (Chwirot and Kuzbicki 2007) which may have a diagnostic 
importance in distinguishing cutaneous melanomas from benign melanocytic lesions. 
Moreover, an escalation of the expression of the COX-2 enzyme during malignant 
melanoma progression has been demonstrated.   
A selective blockage of COX-2 by non-steroid anti-inflammatory drugs (NSAIDs) is 
widely used in anti-inflammatory and analgesic therapeutic strategies. However, 
involvement of COX-2 in carcinogenesis and cancer progression has made this enzyme 
attractive for anti-neoplastic therapy. It has been showed that regular and prolonged 
intake of NSAIDs is associated with 40-50% reduction in colorectal cancer 
incidence(Sinicrope and Gill 2004). Positive results of combination therapy with 
meloxicam, a selective COX-2 inhibitor, and interferon-alpha have been documented in 
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a multicenter phase II trial for cases of metastatic renal cell carcinoma suggesting this 
regimen as a first-line treatment(Shinohara et al. 2009). Another study demonstrated 
that use of a selective COX-2 inhibitor, celecoxib, shows beneficial effects in gliomas 
which are expressing high levels of the enzyme(Cherukuri and Nelson 2004). An 
enhancing effect of the celecoxib to preoperative treatment of non-small cell lung 
cancer has been documented [20]. A study on melanoma cell lines showed both 
cytostatic and cytotoxic effect of cyclooxygenase inhibitors (Chiu et al. 2005) 
It is therefore might be of high interest to identify cases of malignant melanomas 
expressing high levels of COX-2 enzyme since those cases may potentially benefit 
from the treatment with selective COX-2 inhibitors.               
 
1.3.6.8 HSP90 
Shortly after exposure to a significant increase over basal temperature, the cells in most 
tissues dramatically increase the production of a restricted class of proteins collectively 
termed heat shock or stress proteins which serve as central integrators of protein 
homeostasis within cells(Bagatell and Whitesell 2004). Increased expression of the heat 
shock proteins enhances cell survival in tissues damaged by a variety of stressors 
including heat, heavy metals, hypoxia, or acidosis. One of such proteins, heat shock 
protein 90 (Hsp90), is required for the stability and function of a number of 
conditionally activated and/or expressed signalling proteins, as well as multiple 
mutated, chimeric, or overexpressed signalling proteins, which promote cancer cell 
growth and survival(Neckers and Ivy 2003). Despite the name “heat shock protein” 
most chaperones are produced under basal conditions at substantial levels and even 
under non-stressed conditions the Hsp90 comprises as much as 1% to 2% of total 
cellular protein. HSP90 (90kDa) is a highly conserved and essential stress protein that
 
is 
expressed in all eukaryotic cells (Pratt and Toft 2003). The complete HSP90 protein is 
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a homodimer of two identical subunits. Each monomer has four distinct domains; a 
highly conserved N-terminal (NTD) domain (25 kDa); a "charged linker" region that 
connects the N-terminus with the middle domain; a middle domain (MD) with 
molecular mass of 40 kDa and a 12 kDa C-terminal domain (CTD)(Prodromou and 
Pearl 2003). The N-terminal domain contains the ATP-binding site and is responsible 
for intrinsic ATPase activity of HSP90. Structural alterations driven by the hydrolysis 
of ATP to ADP in this domain play an essential role in the chaperoning activity of the 
HSP90 protein.  This domain is also the binding site of the structurally unrelated 
natural products geldanamycin and radicicol as well as the growing number of 
semisynthetic compound which are studied as potential anti-neoplastic agents. The 
middle domain is a major site of client protein binding [5]. The c-terminal serves as a 
dimerization site. Increased expression of chaperone protein HSP90 has been 
demonstrated in several human neoplasias which may reflect the ability of malignant 
cells to maintain homeostasis in a hostile environment(Picard 2002). In addition to 
facilitating cell survival the HSP90 also allows tumour cells to tolerate alterations from 
within, including mutations of critical signalling molecules that would otherwise be 
lethal(Takayama et al. 2003).  
Increased expression of HSP90 has been demonstrated in several human cancers 
including those of salivary gland (Vanmuylder et al. 2000), bladder (Lebret et al. 2003), 
endometrium (Nanbu et al. 1998), liver (Lim et al. 2005), oesophagus (Faried et al. 
2004), breast (Pick et al. 2007) as well as melanoma (McCarthy et al. 2008). Generally, 
HSP90 protein overexpression indicates a poor prognosis in terms of survival and 
response to therapy of neoplastic processes. Elevated HSP90 expression in malignant 
tumours cells plays a key role in protection from spontaneous apoptosis associated with 
malignancy as well as the apoptosis generated by therapy. Besides its prognostic 
importance, the HSP90 has received much attention as a potential target for blocking 
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anti-cancer therapy development. Since the client proteins of the chaperoning function 
of the HSP90 include many oncogenic proteins such as Her2/ErbB2, Akt, Raf-1, Hif-
1a, hormone receptors, mutant p53 and hTERT, it is plausible to speculate that the 
inhibition of HSP90 might lead to the simultaneous degradation of these oncogenic 
proteins(Hahn 2009). The use of currently available selective HSP90 inhibitors, 
geldanamycin and radicicol, as well as theirs synthetic analogs is currently 
studied(Taldone et al. 2008). Studies on melanoma cell lines showed a positive effect 
with heat shock proteins inhibitors providing a base for the clinical use of this 
therapeutic strategy in malignant melanomas(Babchia et al. 2008; Beloueche-Babari et 
al. 2010; Burger et al. 2004). As such, the estimation of the HSP90 protein expression 
in malignant melanomas may provide both prognostic and therapeutic information. 
                
1.3.6.9 BRAF gene mutation V600E 
The responses that cells make to their environment are controlled by a series of highly 
conserved signalling pathways which transmit signals from the cell surface to the 
nucleus through a series of protein cascades. One of such cascades is the 
RAS/RAF/MEK/ERK pathway(FIG) (Marais and Marshall 1996). In this pathway 
growth factors bind to and activate receptor tyrosine kinases (RTKs) which stimulate 
activation of RAS-proteins: K-RAS, H-RAS and N-RAS. RAS proteins are attached to 
the inner surface of the plasma membrane. In their active form, they bind to and recruit 
RAF proteins from the cytosol to the plasma membrane where RAF is activated. RAF 
is a group of serine/threonine protein kinases which includes A-RAF, B-RAF, and C-
RAF. In the signal cascade, RAF phosphorylates and activates a second protein kinase 
called MEK, which in turn phosphorylates and activates a third protein kinase - ERK. 
The ERK phosphorylates proteins in the cytosol, and it also translocates to the 
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nucleus, where it phosphorylates proteins such as transcription factors(Ballif and 
Blenis 2001). Classically, this pathway is associated with proliferation and also 
regulates differentiation, apoptosis and survival(Garnett and Marais 2004). Alterations 
which activate the members of this pathway are implicated in development of many of 
the human malignancies(Davies et al. 2002; Mercer and Pritchard 2003). The b-raf 
gene mapped to chromosome 7q34 which encodes one of the RAF kinases, BRAF, 
often shows activating mutations in human neoplasias. Mutation of this gene have been 
reported in gliomas(Dougherty et al. 2011), colorectal cancers(Baldus et al. 2010), 
adrenocortical carcinomas[8], prostate cancer(Jeong et al. 2008), germ cell 
tumours(McIntyre et al. 2005), papillary thyroid cancers(McIntyre et al. 2005) as well 
as melanomas(Gray-Schopfer et al. 2005). It has been shown that approximately 42% 
of melanomas (Rubinstein et al. 2010) and 80% of benign nevi (Pollock et al. 2003) 
harbour activating BRAF mutations. Most commonly, the valine at amino acid 600 is 
replaced by glutamate (V600E) through mutation of a single nucleotide: GTG to GAG. 
It has been shown that incidence of BRAF gene mutation in malignant melanoma 
correlates with its progression which implicates prognostic importance (Dong et al. 
2003). The incidence of BRAF mutation is increasing towards the advanced stage of 
disease and is maximal in metastatic malignant melanomas(Shinozaki et al. 2004). The 
detection of the activating BRAF mutation in malignant melanomas may also have a 
therapeutical importance. Specific BRAF kinase inhibitors, such as sorafenib, are 
undergoing rapid clinical development and promising data on efficacy have been 
demonstrated. It has been shown that use of sorafenib enhances the response of 
melanoma to regional chemotherapy (Augustine et al. 2010). Anti-cancer activity of 
sorafenib in malignant melanomas has been demonstrated in several studies (Eisen et 
al. 2011; Escudier et al. 2007). Among the latest inhibitors of the aberrant BRAF 
activity is a synthetic compound PLX4032 (vemurafenib). Recent clinical data from 
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clinical trials indicate that PLX4032 causes tumour regression and prolongs survival in 
patient with advanced malignant melanoma (Chapman et al. 2011; Lee et al. 2010). It 
therefore seems reasonable to assume that the detection of a V600E BRAF mutation in 
malignant melanomas may have prognostic as well as clinical importance. 
 
2. AIMS OF THE STUDY. 
 
- To analyze the expression of proteins CD40, CD44, Bcl-2, CD117, COX-2 and 
HSP90 in fine needle aspirates from metastatic malignant melanomas and 
correlate the expression to histopathological parameters of the primary tumours 
as well as rate of cell proliferation estimated by Ki-67 expression. (Papers I and 
II). 
 
- To analyze the expression of proteins S100A, S100B, CD44 and Bcl-2 in 
formalin-fixed paraffin-embedded sections from primary benign and malignant 
melanocytic tumours as well as metastases of malignant melanomas and 
compare the expression to histopathological parameters and the rate of cell 
proliferation estimated by Ki-67 expression in the primary tumours. (Paper III). 
 
- To analyze frequency of BRAF V600E mutation in fine needle aspirates from 
malignant melanomas and compare and compare the results to the clinical and 
histopathological parameters of the primary tumours as well as rate of cell 
proliferation estimated by Ki-67 expression (Paper IV).    
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3. MATERIAL AND METHODS. 
3.1 Protein expression 
A series of archived non-fixed frozen cytospin preparation slides from fine needle 
aspirates of melanoma metastases were used for immunocytochemical detection of 
proteins CD40, CD44, Bcl-2, CD117, COX-2, HSP90 and Ki-67 (Papers I, II and III). 
Ninety cases (57 males and 33 females, age ranging from 25 to 89 years, mean 64 
years) were used in Paper I, thirty cases (18 males and 12 females, aged between 34 
and 90 years, mean 67 years) were used in Paper II and forty-four cases (25 males and 
19 females, age range 28-90 years, mean 66 years) were used in Paper III. Initially, the 
fine needle aspirates were obtained using an aspiration procedure as described by J. 
Zajicek (Zajicek 1974). The leftover material after initial diagnostic work-up was 
suspended in isotonic phosphate buffered saline and centrifuged on three-well 
cytospine slides using approximately 10
5
 cell concentration. The cytospine slides were 
then air dried, placed in plastic containers and stored at -20C
0
. After retrieval from the 
archive the containers were allowed to reach the environmental temperature in order to 
avoid cell lysis. The slides were then taken from the containers and placed on 
slideholders. A three step alkaline phosphatase immunocytostaining technique as 
described earlier(Tani et al. 1988) was used for the detection of the CD40, CD44, Bcl-
2, CD117, COX-2 and HSP90 proteins in cell cytoplasm and cell membrane. A three 
step peroxidase-avidin-biotin immunocytostaining technique for detection of the 
nuclear Ki-67 antigen was applied as previously described (Skoog et al. 1990). The 
slides were counterstained with Giemsa staining and mounted using water-based 
mounting media.  In all immunoassaying series, reactive lymphatic nodules were used 
as positive control and omitting the step of application of the primary antibody served 
as a negative control. 
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A series of archived formalin-fixed, paraffin-embedded material from benign nevi, 
primary and metastatic melanomas were used for detection of proteins S100A1, S100B, 
Bcl-2 and Ki-67 (Paper III). One hundred and twenty-six patients (32 males and 94 
females with range 11-94 years, mean 43 years) were included in this retrospective 
study. After retrieval from the archive, four-micrometer thick sections on preparation 
slides were made. The preparations were subsequently deparaffinized and rehydrated 
and used for immunohistochemical staining procedure utilizing a high-sensitivity 
labelled strepravidin-biotin (LSAB) technique (LSAB+ it, Dakopatts AB, Sweden) 
(Giorno 1984). A commercially available antibodies to cytoplasmatic and membranous 
proteins S100A1 (clone DAK-100A1/1), S100B (clone DAK S100B/2), CD44 (clone 
DF 1485), Bcl-2 (clone 124) and nuclear protein Ki-67 (clone MIB-1) were used in the 
study. A technique for heat-induced microwave antigen retrieval was used as described 
earlier(Shi et al. 1991). Omitting application of primary antibody was used as a 
negative control. Slides, known to express the analyzed proteins, containing brain 
tissue, squamous carcinoma and breast carcinoma were used as positive controls for 
S100A1 and S100B, Bcl-2 and CD44 markers, respectively. The slides were 
counterstained with Haematoxylin-Eosin stain and mounted using water-based 
mounting media. Three pathologists independently reviewed the archived primary 
slides from respective cases. Then a consensus was reached among the pathologists in 
all cases regarding the type of melanocytic tumour using criteria as proposed by world 
health organization classification of skin tumours. All cases were stratified to the 
following morphological groups: intradermal nevi, compound nevi, dysplastic nevi, 
malignant melanoma and metastatic melanoma. 
All cells with preserved structure showing clear cytoplasmatic/membrane staining 
(CD40, CD44, Bcl-2, CD117, COX-2 and HSP90) or nuclear staining (Ki-67) were 
scored as positive. The number of positive cells was registered using electronic cells 
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counter (CelloDiff III, Analysis Instrument AB, Sweden). Cells with damaged cell 
membrane or artefacts were not included in scoring results. The results were given as 
percentage of positive cells divided by the total cell number in the analyzed area. The 
scores were documented using Microsoft ® Excel ® software. Data related to the 
histopathological features of the primary tumours as well as evaluated clinical 
parameters were available either from a computerized file archive system at Karolinska 
Hospital (SymPathy, TietoEnator AB, Sweden, Papers I and II) or archived recordings 
at Latvian Centre of Pathology (Paper III). Statistical analysis was performed using 
Statistica ™ software (Statsoft AB, Uppsala, Sweden). 
 
3.2 BRAF gene mutation V600E 
A series of forty-four cases of metastatic malignant melanomas (25 males and 19 
females, age range 28-90 years, mean 66 years) was used for detection of BRAF 
V600E mutation (Paper IV). All patients were previously surgically treated for primary 
malignant melanomas and the diagnosis was histologically verified. The patients were 
referred to the cytology department at Karolinska Hospital between 2006 and 2007 for 
fine-needle aspiration of lesions suspicious for metastatic disease. The aspirations were 
performed as described earlier (Zajicek 1974) and one part of aspirates was used for 
diagnostic work-up including microscopy and immunocytostaining, and the other part 
of the aspirates was suspended in phosphate-buffered saline (pH 7,4). The saline-
suspended material was then centrifuged, the supernatant was removed and the pellet 
was frozen at -20
0
C. The material was retrieved from the archive and used for 
genotyping of BRAF V600E mutation. Extraction of the genomic DNA was performed 
using Wizard ® Genomic DNA Purification Kit (Promega Corporation, Madison, WI, 
USA). The concentration of DNA was measured using a Nanodrop ND-1000 
spectrophotometer (Nanodrop, Wilmington, DE, USA). A 5’ nuclease assay for allelic 
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discrimination method was used for genotyping of the exon 15 V600E mutation of the 
BRAF gene. A Tag-Man MGB biallelic discrimination system was used as previously 
described(Livak et al. 1995). Probes and nucleotides were synthesized in 40 
concentrations by Applied Biosystems (Foster City, CA, USA) using the Assay-by-
Design ordering system. PCR’s were performed on ABI prism Sequence Detection 
System 7000 (Applied Biosystems. The 25µl PCR contained 1x of the TagMan 
Universal PCR Master Mix, No AmpErase UNG, 1x of the assay probe and primer mix 
(forward primer CATGAAGACCTCACAGTAAAAATAGGTGAT, reverse primer 
GGATCCAGACAACTGTTCAAACTGA, VIC MGB probe 
CCATCGAGATTTCACTGTAG, FAM MGB probe 
CCATCGAGATTTCTCTGTAG), and 25-50 ng of the sample genomic DNA
 
and was 
performed on 96-well optical PCR plates. Each genotyping
 
plate contained no DNA 
template controls, and random samples
 
were run as duplicates to confirm the successful 
genotyping
 
process. SDS version 2.0 software was used to analyze real-time
 
PCR data 
and end-point fluorescence. Genotyping data were exported
 
from SDS software into 
Microsoft ® Excel ® programme data sheets for further analysis. 
 
3.3 Statistical analysis. 
Statistica ® software (Statsoft ™ AB, Uppsala, Sweden) was used for performing 
statistical calculations. Differences in means were analyzed using paired and unpaired 
t-test when appropriate. ANOVA test was used for overall comparison of 
immunoreactivity and diagnostic categories.  A Pearson r2-correlation test was used for 
analysis of explanatory variables. The p-value levels of significance were set at ≤0.05.   
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4. RESULTS AND DISCUSSION. 
  
4.1 Protein expression. 
The immunostaining for antigens CD40, CD44, CD117, COX-2, HSP90 and Bcl-2 
resulted in a cytoplasmic and membranous staining pattern with dominance of the later 
in staining pattern for CD44.  The staining of the Ki-67 protein was strictly nuclear 
with varying intensity. All cells showing weak to strong were scored as positive.   
 
 
4.1.1 S100. 
S100 is a dimeric protein composed of α and β subunits, which regulates cellular 
cytoskeletal system as well as plays a role in cell cycle regulation, cell division and 
cell-to-cell communication (Zimmer et al. 1995). Since a majority of malignant 
melanomas express S100, immunochemical detection of this protein is used for purpose 
of differential diagnose. At present a total of 25 S100 isoforms are identified and 
several studies have been analyzing expression of different S100 variants in 
melanocytic tumours. Whereas a lot of studies have been analyzing level of the S100 
variants in serum, only a few studies have been focused on analysis of S100 expression 
in primary and metastatic melanomas (Keijser et al. 2006; Nonaka et al. 2008). In paper 
III we have analyzed expression of S100A1 and S100B in benign melanocytic tumours, 
primary melanomas as well as melanoma metastases using monoclonal antibodies 
against these proteins. The fraction of S100A1 positive cells was lower in the group of 
benign melanocytic lesions with means of 41.1%, 55.7% and 74% for intradermal, 
compound and dysplastic nevi, respectively, as compared to that of primary melanomas 
and melanoma metastases with mean of 85% and 86.0, respectively. The difference in 
the S100A1 expression in benign and malignant melanocytic tumours reached 
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statistical significance (r=0.61; r
2
=0.376). In contrary, the fraction of S100B positive 
cells was higher in the group of benign melanocytic tumours as compared to that of 
malignant tumours with means of 86.3%, 88.4%, 75.6%, 47.7% and 52.5% for 
intradermal, compound and dysplastic nevi, and primary and metastatic melanomas, 
respectively. A statistically significant difference in respect to S100B in groups of 
benign and malignant melanocytic tumours was observed in our study (r=-0.627; 
r
2
=0.393). This observation allows us to conclude that simultaneous analysis of 
S100A1 and S100B proteins in melanocytic lesion may be used in purpose of 
differential diagnose between benign and malignant tumours. Interestingly, the staining 
of S100A1 in malignant melanomas was more intensive in areas with increased 
proliferative activity of the tumour cells as estimated by Ki-67. This observation allow 
us to assume that the activity of the S100A1 might be related to cell cycle regulation, 
which is in concordance with study on cells cultures (Zimmer et al. 1995). Further 
studies are needed to explain the discrepancy between elevated serum level of S100B 
and its decreased expression in tumour cells.  
 
 
4.1.2 CD40. 
CD40 was originally described as a type I transmembrane glycoprotein on B 
lymphocytes It plays an important role in the immune response mediating maturation of 
B-cells as well as regulating the response of regulatory T cells both during their 
development (Foy et al. 1995) and their encounter with the antigen (Cayabyab et al. 
1994). CD40 molecule is expressed in non-haematopoietic tissues including tumours 
and has been suggested to have a critical role in the processes of cell proliferation, 
migration and apoptosis (Pirozzi et al. 2000). Expression of CD40 and its prognostic 
significance in primary cutaneous melanomas has been described (van den Oord et al. 
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1996). Thus, it was of high interest to analyze the expression of CD40 protein in 
metastatic malignant melanomas and evaluate if the expression levels might be 
correlated to well known parameters of melanoma progression and prognosis such as 
survival rate and histomorphological properties of corresponding primary tumours. In 
Paper I we demonstrated that metastatic melanomas are a heterogeneous tumour in 
respect to CD40 expression. This observation is in agreement with previous studies 
showing variable frequencies of CD40 expression in melanoma cells (Pirozzi et al. 
2000; Thomas et al. 1996; van den Oord et al. 1996). In our series, the fraction of the 
CD40-positive cells in metastatic melanomas varied from negative to maximal value of 
58.9% with mean 8.5% and median 3.0%. Moreover, the fraction of CD40 positive 
cells in metastatic melanomas was higher in patients with clinical stage III, median 
22.8%, as compared to that of clinical stage II with median number of 3.2%. However, 
no significant correlation was found between expression of the CD40 and 
histopathological parameters of the corresponding primary tumours. Median percentage 
of CD40 positive cells in melanoma metastases originating from melanomas with 
Clark’s invasion levels 2, 3, 4 and 5 were 1.3%, 2.1%, 2.4% and 4.2% in, respectively. 
Median percentages of CD40 positive cells were 3.4%, 2.6% and 0.4% for metastases 
from primary tumours with thickness equal or less than 1mm, 1mm to 4mm, and more 
than 4mm, respectively. No correlation between survival after diagnosis of first 
metastasis and expression of CD40 was found in our study. It is therefore plausible to 
speculate that other pathways than those regulated by CD40 are involved in progression 
of malignant melanomas. However, the expression of CD40 might reflect unique 
features of an individual tumour rather than whole tumour group. A study on melanoma 
cell lines has demonstrated that the CD40 molecule may play a role in the complex 
interactions underlying recruitment and/or expansion of  tumour recognizing' immune 
effectors, thus identifying CD40 as one of the molecules involved in melanoma cell-
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mediated co-stimulation of anti-CD3-induced human T cell proliferation(Pirozzi et al. 
2000). Thus, we speculate that the expression of the CD40 protein in malignant 
melanomas reflects ability of melanocytes act as “non-professional” antigen-presenting 
cells and reflects individual properties of the tumour and the patient. 
 
4.1.3 CD44. 
Several recent studies on melanoma cell cultures showed that CD44 protein plays an 
important role in regulating adhesion and migration of melanoma cells, thus 
contributing to theirs high metastatic potential(Hernandez et al. 2011; Kozlowska et al. 
2004; Weimann et al. 2003). However, only a few studies have been focused on role of 
CD44 molecule in malignant melanomas in vivo. One study reported an increased 
metastatic risk and reduced survival in tumours with high expression of CD44 (Dietrich 
et al. 1997). In the present study we have analyzed the expression of CD44 in benign 
melanocytic tumours (Paper III), primary melanomas (Paper III) as well as metastatic 
melanomas (Papers I and III) and compared the expression levels to histopathological 
parameters of the corresponding primary tumours as well as survival. Immunostainig of 
the CD44 antigen in all melanocytic tumours in all our studies resulted in membranous 
staining pattern obviously reflecting the nature of CD44 as a transmembrane 
glycoprotein. In the group of benign melanocytic lesions the mean percentage of CD44 
expression was 60.4%, 62.1%, and 52.1%, with standard deviations (SD) of 33.5, 33.5 
and 35.1 for groups of intradermal nevi, compound nevi and dysplastic nevi, 
respectively (Paper III). The mean percentage of the CD44 expression in primary 
melanomas was 59.4% (SD=33.7) (Paper III). Metastatic melanomas showed mean 
percentage of 76.1% (SD=22.5) (Paper I) and 55.7% (SD=42.0) (Paper III). The 
percentage of CD44 positive cells in metastatic melanomas showed a tendency to be 
lower in patients with long survival after the first metastasis which is in concordance 
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with a previous study(Dietrich et al. 1997). However, this tendency did not reach 
statistical significance in our series (r-value= 0.12). No significant correlation was 
found between the expression of the CD44 protein in metastatic melanomas and 
histomorphological properties of the corresponding primary tumours. Benign and 
malignant melanocytic tumours had similar expression of CD44. On the basis of our 
results we may conclude that melanocytic neoplasias of benign as well as malignant 
character constitutively express the CD44 antigen which suggests functional and/or 
structural involvement of the CD44 molecule in these tumours. However, we could not 
demonstrate a statistically significant difference in CD44 expression in various groups 
of melanocytic lesions. It should be pointed out that in our studies a monoclonal 
antibody which is reactive with all more than 20 known isoforms of CD44 protein was 
used. Thus, we were not able to estimate the expression of individual variants of CD44 
in melanocytic tumours. A heterogeneous type of expression of CD44 in human 
cancers has been reported (Goodison and Tarin 1998) which allow us to hypothesise 
that progression of melanocytic tumours, in analogy with other neoplastic processes, 
involves a specific isoform variant of CD44 protein rather than the entire class of these 
proteins. Further studies are needed to confirm this hypothesis. 
 
4.1.4 Bcl-2. 
The mitochondrial pathway of apoptosis constitutes one of the main safeguards against 
tumorigenesis. The Bcl-2 family includes the central members of this pathway that 
regulate cell fate through the control of mitochondrial outer membrane 
permeabilization (MOMP). Bcl-2 proteins are often dysregulated in cancer, leading to 
increased survival of abnormal cells (Llambi and Green 2011). It has been shown that 
dysregulation of Bcl-2 proteins appears of critical importance for melanoma cell 
survival and drug resistance (Eberle and Hossini 2008). Elevated levels of Bcl-2 protein 
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have been demonstrated in conjuctival nevi as compared to conjuctival melanoma, 
indicating the diagnostic application of the Bcl-2 analysis in conjuctival melanocytic 
lesions (Westekemper et al. 2011). In one study, an increase of Bcl-2 protein levels has 
been demonstrated during melanoma progression from localized to metastatic disease 
(Zhang and Rosdahl 2006). Several studies showed that overexpression Bcl-2 in 
melanomas is associated with tumour progression, growth, decreased survival as well 
as malignant phenotype of melanomas (Trisciuoglio et al. 2005; Utikal et al. 2002; 
Vlaykova et al. 2002). However, another study showed that there is no association 
between Bcl-2 expression and survival in cutaneous melanomas (Espindola and Corleta 
2008). Besides its possible prognostic importance, the analysis of Bcl-2 in malignant 
melanomas may have therapeutical importance. Moreover, targeting survival pathways 
which control the Bcl-2 protein expression is suggested as one of possible therapeutic 
strategies in malignant melanomas (Eberle and Hossini 2008). Oblimersen, an antisense 
oligonucleotide directed against Bcl-2, decreases expression of Bcl-2 by blocking the 
translation from mRNA. One study showed that a progression-free survival as well as 
overall survival is improved in patients with metastatic melanoma who receive 
oblimersen and dacarbazine as compared to those received only dacarbazine (Bedikian 
et al. 2006). Thus, it was of high interest for us to analyze expression of Bcl-2 in benign 
melanocytic tumours, primary melanomas and melanoma metastases. In Paper I we 
analyzed expression of Bcl-2 in fine-needle aspirates from melanoma metastases in 
ninety patients. In Paper II, the expression of Bcl-2 was analyzed on formalin fixed 
material from 45 intradermal (IN), 27 compound (CN) and 8 dysplastic nevi (DN) as 
well as 32 primary and 14 metastatic melanomas. The expression of Bcl-2 was higher 
in the group of benign melanocytic tumours with means of 46.6%, 34.7% and 38.6% 
for IN, CN and DN, respectively, as compared to that of primary and metastatic 
melanomas with means of 3.0% and 4.0%, respectively (Paper III). This trend was also 
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demonstrated in Paper I where mean of Bcl-2 expression in metastatic melanomas 
consisted 8.5%. Interestingly, the range of Bcl-2 expression was more prominent in 
groups of benign melanocytic tumours with variation of the mean percentage between 
36.0%-57.1, 20.7%-48.6% and 4.1-73.1 in IN, CN and DN, respectively, as compared 
to that of 0.2%-5.8% and 1.2%-9.2% in primary and metastatic melanomas, 
respectively. Staining for Bcl-2 in melanomas had more intensive character in areas 
with increased proliferative activity as assessed by Ki-67 antibody. A significant 
correlation between Bcl-2 expression and shorter survival after first melanoma 
metastasis was demonstrated in Paper I. No correlation was found between Bcl-2 
expression in metastases and Clark’s invasion level as well as thickness of the 
corresponding primary tumours. The results allow us conclude that melanomas have 
decreased rates of Bcl-2 expression as compared to that of benign melanocytic tumours. 
However, the tumours with overexpressed Bcl-2 show shorter survival which allow to 
select melanoma cases with more aggressive clinical course. Malignant melanomas are 
heterogeneous in respect to bcl-2 expression which may be used in patient selection for 
individual treatment approach with specific bcl-2-blocking therapy.                         
 
4.1.5 Ki-67 
Since its discovery by Gerdes (Gerdes et al. 1983) in 1983, assessment of Ki-67 
became an important method for the evaluation of proliferating cell fraction in benign 
as well as malignant tumours. The strict association of Ki-67 expression with G1, S, 
and G2, phases of the cell cycle and mitosis and absence in resting cells (G0-phase) as 
well as high reproducibility made it an excellent tool for determining the so-called cell 
growth fraction. Estimation of growth fraction by analysis of Ki-67 has independent 
prognostic value for survival, tumour progression and recurrence, which repeatedly 
been proven in uni- and multivariate analyses of several human malignancies (Scholzen 
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and Gerdes 2000). Many studies have focused on analysis of growth fraction in 
melanocytic tumours of benign type as well as melanomas. Increased rates of 
proliferating cell fractions have shown significant association with shorter survival in 
patients with uveal (Karlsson et al. 1996), primary cutaneous (Henrique et al. 2000; 
Ladstein et al. 2010) and disseminated melanomas (Vlaykova et al. 1999). Moreover, 
analysis of proliferation rate by Ki-67 helps to discriminate Spitz nevi from malignant 
melanomas (Kanter-Lewensohn et al. 1997; Vollmer 2004) which makes it a useful 
tool in diagnostic work-up of melanocytic tumours. In our studies we have focused on 
analysis of proliferating rate as estimated by Ki-67 in fine-needle aspirates from 
metastatic malignant melanomas (Paper I, II and IV) as well as formalin-fixed, 
paraffin-embedded benign melanocytic tumours, primary melanomas and metastatic 
melanomas. In all series, immunostaining of Ki-67 antigen by monoclonal antibody 
MIB-1 resulted in strict nuclear staining of varying intensity. Expression levels of Ki-
67 antigen varied in benign melanocytic tumour, primary melanomas and metastatic 
melanomas (Table). It can be seen from the table that growth fraction in melanocytic 
tumours was lower than that of malignant tumours. There was no overlap in 
proliferating fraction range of benign tumours (min=0.48%, max=1.84%) and 
malignant melanomas (min=5.9%, max=64.6%). This observation reached statistical 
significance (Paper III, r=0.814, r
2
=0.663) and is in concordance with previous studies 
that showed the use of the growth fraction assessment in melanocytic lesion for 
discerning benign and malignant tumours. A significant correlation between growth 
fraction in metastatic melanomas and shorter survival rate was observed in Paper I 
(Pearson r= -0.317). The rate of cell proliferation was higher in primary melanomas 
which were 3mm or thicker compared to those less than 3mm (Paper III). However, 
this tendency was not statistically significant which was in line with similar 
observations in Paper I and IV. The mean percentage of growth fraction was lower 
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(20.7%) in melanomas without BRAF V600E mutation as compared to that of mutated 
tumours (26.2%), Paper IV. No difference was observed between growth fraction in 
malignant melanomas and time of developing metastatic disease. Summarizing the 
above we conclude that assessment of proliferating rate by detection of Ki-67 antigen 
in melanocytic tumours may have an important role in diagnostic work-up helping to 
discern benign and malignant tumours as well as contribute as a being a prognostic 
marker. 
 
 
4.1.6 CD117. 
Detection of the CD117 (KIT) protein in human malignancies has been of great interest 
from therapeutical, aetiological, diagnostic and prognostic perspective. Expression of 
CD117 in colorectal cancers, breast cancers, sarcomas, renal cell cancers and ovarian 
cancers has been associated with worse prognosis (Medinger et al. 2010). Detection of 
CD117 protein plays a diagnostic role in GISTs (de Silva and Reid 2003). Moreover, 
detection of an activating mutation in the KIT gene is used to identify individual 
tumours which may be sensitive to a specific kinase-blocking therapy with PLX4032, 
imatinib mesylate or other blocking agents in malignancies which are depending on 
MAPK (Mitogen Activated Protein Kinase) pathway (Miettinen and Lasota 2005). 
Several studies have been focused on expression of CD117 in primary melanomas. In 
one study the authors showed that expression of CD117 in melanocytic tumour may 
help to differentiate melanomas from benign nevi, but it did not correlate with 
prognosis (Oba et al. 2011). However, in a recent large-scale study on more than 500 
cases of malignant melanomas, both overexpression of CD117 and presence of mutated 
KIT gene have been showed to correlate with a significantly shorter survival(Kong et 
al. 2011). In Paper II we analyzed the expression of CD117 in fine-needle aspirates 
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from metastatic melanomas. Immunostaining with a monoclonal CD117 antibody 
resulted in cytoplasmic staining pattern of varying intensity. Fourteen out of total thirty 
cases (46%) of metastatic melanomas showed CD117 expression. The fraction of 
CD117 positive cells ranged from 0% to 93% with mean of 12.2%. The expression of 
CD117 was similar in cases of monometastatic and multimetastatic melanomas with 
mean of 12.8 and 11.0, respectively. We have compared the expression of the CD117 
in melanoma metastases with histopathological properties of corresponding primary 
tumours as well as rate of cell proliferation. No significant correlation was found 
between CD117 expression and Clark’s invasion level, tumour thickness or rate of cell 
proliferation as estimated by Ki-67. We therefore conclude that metastatic melanomas 
are heterogeneous in respect to expression of CD117 and a small proportion of 
metastatic melanomas (46%) express this antigen. Only 16% of the tumours in our 
study showed expression of CD117 in more than 30% of tumour cells. This observation 
allows us to speculate that the MAPK pathway which has been shown to play an 
important role in of malignant melanomas is more often activated via other signalling 
pathways than KIT cascade. Studies on specific therapy with KIT blockers on 
unselected melanoma patients showed lack of clinical efficacy of this treatment (Kim et 
al. 2008; Ugurel et al. 2005). However, an increased frequency of KIT aberrations has 
been demonstrated in mucosal and acral melanomas but not in melanomas in areas 
from intermittent sun exposure (Curtin et al. 2006; Satzger et al. 2008). This shows that 
there is a subset of melanomas which still may represent targets for specific therapy 
based on KIT blockade, but an individual approach is needed for selection of patients. 
Thus, analysis of CD117 overexpression and KIT gene mutation may comprise a basis 
for individual approach in treatment of malignant melanoma. 
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1.4.7 COX-2 
A range of experimental and clinical evidence has showed the importance of COX-2 
protein in cancer development (Coussens and Werb 2002; Greenhough et al. 2009). 
Increased expression of COX-2 protein has been demonstrated in most human 
malignancies and it may have both prognostic and therapeutic implication. (Ghosh et al. 
2010). It has been suggested that upregulation of COX-2 may result from activation of 
Ras and mitogen-activated protein kinase (MAPK) pathway(Sheng et al. 1998) – the 
molecular signalling which has been demonstrated to have an important role in 
melanoma progression(Fecher et al. 2008). Thus, specific blocking treatment directed 
against the COX-2 protein may have a therapeutic importance in malignant melanomas. 
Several studies have analyzed COX-2 expression in melanocytic tumours. An increased 
expression of COX-2 in malignant melanomas compared to benign melanocytic lesions 
has been shown in one study suggesting its diagnostic implication (Minami et al. 2011). 
Another study demonstrated that overexpression of COX-2 in malignant melanomas 
has significant correlation with disease-free survival (Becker et al. 2009). However, 
collective analysis of immunohistochemical data on the COX-2 expression in 
melanomas, presented by different researchers, shows lack of consistency and different 
expression patterns of COX-2 were reported (Kuzbicki et al. 2009). In Paper II focused 
on immunocytochemical analysis of COX-2 expression in fine-needle aspirates from 
malignant melanomas. In our series all melanoma cases showed expression of COX-2 
protein with positive cell fraction ranging from 5% to 93% (mean=49.2%, 
median=49.0). In cases with multiple melanoma metastases, the median number of 
COX-2 positive melanoma cells was higher as compared to that of tumours with a 
single metastasis. A median of 62% and 41% was found in multimetastatic and 
monometastatic tumours, respectively. We have compared the expression of the COX-2 
with histopathological prognostic parameters such as Clark’s invasion level, tumour 
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thickness in millimetres as well as proliferation rate as detected by Ki-67. Although 
there was a variation in tumours with different invasion levels and thickness, this 
relationship did not reach a statistical significance. Our observations suggest that 
expression of the COX-2 protein in metastatic melanomas lacks prognostic importance. 
However, in our study we have shown that all melanomas express the COX-2 which 
suggests involvement of this protein in signalling pathways responsible for melanoma 
development or/and progression. Thus, cases overexpressing this COX-2 may represent 
candidates of a selective targeted therapy of malignant melanomas with COX-2 
inhibitors (e.g. celecoxib) which is currently being evaluated (Bhatt et al. 2010; Wilson 
2006). 
 
4.1.8 HSP90 
The Hsp90 chaperone is a main regulator of the stability and activity of more than 200 
proteins including oncoproteins such as Her2, Akt, Bcr-Abl, c-Kit, EGFR and mutant 
BRAF (Porter et al. 2010). It has been demonstrated that cancer cell use the HSP90 
chaperone machinery to protect an array of mutated and overexpressed oncoproteins 
from missfolding and degradation (Trepel et al. 2010). Therefore, HSP90 is recognized 
as a crucial facilitator of cancer cell survival making it an attractive target for specific 
blocking anti-cancer therapy. Increased expression of HSP90 in malignant melanomas 
has been observed in several studies suggesting it as a marker of tumour progression 
(Becker et al. 2004; McCarthy et al. 2008). In Paper II we analyzed the expression of 
HSP90 protein in tumour aspirates from malignant metastatic melanomas. All tumours 
in our series expressed HSP90 antigen. The fraction of HSP90 positive cells ranged 
from 9% to 98% with median of 84.0% and mean of 68.1%. Different expression levels 
of HSP90 were observed in patients with single and multiple melanoma metastases. In 
monometastatic tumours the median value of HSP90 expression was 64% whereas in 
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multimetastatic disease it was 89%. We also compared the rate of HSP90 expression in 
metastatic melanomas and histopathological properties of the corresponding primary 
tumours such as Clark’s invasion level, tumour thickness as well as proliferating 
fraction as estimated by Ki-67. Although some differences in HSP90 expression in 
relation to these variables were observed the results did not reach statistical 
significance. Moreover, no statistical significant correlation was observed between 
expression of HSP90 and time of developing of metastatic disease. Therefore, our 
results show that despite lack of possible independent prognostic importance, 
expression of the HSP90 molecule can be demonstrated at high rates in metastatic 
melanomas, especially in multimetastatic disease. Thus, metastatic melanomas may 
have the molecular prerequisites to respond to HSP90-blocking therapy. A number of 
studies are currently evaluating anti-tumour activity of a novel class of specific HSP90 
inhibitors in vitro and in vivo, which may present a new therapeutic possibility for 
metastatic melanoma (Mehta et al. 2011).   
 
4.2 BRAF gene mutation V600E 
 The mitogen activated protein kinase (MAPK) pathway plays a key role in melanoma 
development making it an important therapeutic target. In normal melanocytes, the 
tightly regulated pathway conducts extracellular signals from cell membrane to nucleus 
via a cascade of phosphorylation events. In melanomas, dysregulation of the MAPK 
pathway occurs frequently due to activating mutations in the B-RAF and RAS genes or 
other genetic or epigenetic modifications, leading to increased signalling activity 
promoting cell proliferation, invasion, metastasis, migration, survival and angiogenesis.  
Approximately 70 – 80% of acquired melanocytic nevi and 50 – 70% of melanomas 
contain a B-Raf mutation, largely confined to a specific point within the genome, 
designated V600E (B-Raf
v600e
) (Davies et al. 2002; Pollock et al. 2003). High 
 64 
frequency and its presence in both benign and tumours confirms the important role of 
the V600E BRAF gene mutation an early and common genetic alteration in 
melanocytic tumours. Several studies have been focused on analysis of the presence of 
V600E BRAF mutation and melanoma progression. It has been shown that V600E 
BRAF mutation induces melanoma cells to metastasise (Dankort et al. 2009), promotes 
melanoma cell survival (Cartlidge et al. 2008) and is involved in a cascade of molecular 
events in early melanoma development (Cheung et al. 2008). Involvement of this 
mutation in such important steps of melanoma progression has made mutated BRAF 
oncoprotein an attractive target for a specific blocking therapy. Thus, detection of 
BRAF V600E mutation may represent an important step in diagnostic work-up of 
melanomas, providing useful information for individual treatment approach. In Paper 
IV study we analyzed frequency of V600E BRAF gene mutation in fine-needle 
aspirates from metastatic melanomas. We showed that the presence of V600E BRAF 
gene mutation was not restricted to any cytological type of melanomas and seventeen 
out of thirty-nine melanoma metastases (38.6%) showed presence this mutation. 
Interestingly, in the group of melanomas arising from the skin with chronic sun 
exposure (7 cases), only 1 case (14.28%) had this mutation, whereas 15 cases (40.5%) 
were mutated in the group of tumours arising in the skin without chronic sun exposure. 
This observation is in agreement with previous studies which showed that a subset of 
primary melanomas with primary tumours without chronic sun exposure are more 
likely to harbour the BRAF gene mutation (Si et al. 2011). In Paper IV we showed that 
the group of metastatic melanomas harbouring V600E BRAF mutation had higher rate 
of proliferating melanoma cells (26.2%) as compared to that of non-mutated tumours 
(20.7%). Mutated and non-mutated melanomas in our study showed different time of 
development of metastatic disease. While median of 14.4 months was observed in the 
group of mutated tumours, a median of 25.0 months was demonstrated in the group of 
   65 
mutated melanomas. Moreover, correlation to histopathological properties of the 
corresponding primary tumours showed that both tumour thickness and Clark’s 
invasion level were lower in primary tumours with BRAF V600E mutation compared 
to those without mutation. Summarizing the above, we may conclude that malignant 
melanomas are heterogeneous in respect to the presence of BRAF gene mutation and a 
subset of tumours arising from skin without chronic sun exposure are more likely to 
have this type of aberration. Detection of the BRAF V600E gene mutation in metastatic 
melanomas provides additional prognostic information, indicating tumours which may 
have more aggressive biological behaviour and providing a tool for patient selection in 
an individual treatment approach.  
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